WO2020056229A1 - Anti-parasitic immunological compositions - Google Patents
Anti-parasitic immunological compositions Download PDFInfo
- Publication number
- WO2020056229A1 WO2020056229A1 PCT/US2019/050963 US2019050963W WO2020056229A1 WO 2020056229 A1 WO2020056229 A1 WO 2020056229A1 US 2019050963 W US2019050963 W US 2019050963W WO 2020056229 A1 WO2020056229 A1 WO 2020056229A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parasitic
- seq
- peptide
- spp
- leu
- Prior art date
Links
- 230000002141 anti-parasite Effects 0.000 title claims abstract description 74
- 239000003096 antiparasitic agent Substances 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims description 62
- 230000001900 immune effect Effects 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 141
- 150000001875 compounds Chemical class 0.000 claims abstract description 77
- 239000000427 antigen Substances 0.000 claims abstract description 60
- 108091007433 antigens Proteins 0.000 claims abstract description 60
- 102000036639 antigens Human genes 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000002671 adjuvant Substances 0.000 claims abstract description 32
- 241000223997 Toxoplasma gondii Species 0.000 claims abstract description 30
- 230000000890 antigenic effect Effects 0.000 claims abstract description 13
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 230000003071 parasitic effect Effects 0.000 claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 claims abstract description 4
- 101800001415 Bri23 peptide Proteins 0.000 claims abstract description 3
- 102400000107 C-terminal peptide Human genes 0.000 claims abstract description 3
- 101800000655 C-terminal peptide Proteins 0.000 claims abstract description 3
- 241000282414 Homo sapiens Species 0.000 claims description 38
- 208000015181 infectious disease Diseases 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 24
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 14
- 241000282412 Homo Species 0.000 claims description 12
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 12
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims description 11
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims description 11
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 5
- 102000043129 MHC class I family Human genes 0.000 claims description 5
- 108091054437 MHC class I family Proteins 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- 150000003839 salts Chemical group 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- DHIVBEZCBBHIPZ-UHFFFAOYSA-N 1-aminoimidazolidin-2-one Chemical class NN1CCNC1=O DHIVBEZCBBHIPZ-UHFFFAOYSA-N 0.000 claims description 4
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 claims description 4
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims description 3
- 241000223836 Babesia Species 0.000 claims description 3
- 241001235572 Balantioides coli Species 0.000 claims description 3
- 241000223935 Cryptosporidium Species 0.000 claims description 3
- 241000205707 Cystoisospora belli Species 0.000 claims description 3
- 241001126690 Cytauxzoon felis Species 0.000 claims description 3
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- 241000223924 Eimeria Species 0.000 claims description 3
- 241000224432 Entamoeba histolytica Species 0.000 claims description 3
- 241000224466 Giardia Species 0.000 claims description 3
- 241000948220 Histomonas meleagridis Species 0.000 claims description 3
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical class [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- 241000222722 Leishmania <genus> Species 0.000 claims description 3
- 241001147662 Neospora caninum Species 0.000 claims description 3
- 241000224539 Pentatrichomonas hominis Species 0.000 claims description 3
- 241000224016 Plasmodium Species 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 241000224003 Sarcocystis Species 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 241001533587 Spironucleus Species 0.000 claims description 3
- 241000223777 Theileria Species 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 241000224527 Trichomonas vaginalis Species 0.000 claims description 3
- 241000224528 Tritrichomonas Species 0.000 claims description 3
- 241000223104 Trypanosoma Species 0.000 claims description 3
- IADUEWIQBXOCDZ-UHFFFAOYSA-N azetidine-2-carboxylic acid Chemical class OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000008680 babesiosis Diseases 0.000 claims description 3
- 208000007456 balantidiasis Diseases 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229940007078 entamoeba histolytica Drugs 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- WRSUAEFOSNASPN-JBRKIFEHSA-N (2s)-2-[[2-[[(2s)-1-[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-methylsulfanylbutanoy Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 WRSUAEFOSNASPN-JBRKIFEHSA-N 0.000 claims description 2
- UGKLUDVFRIAEDG-JBRKIFEHSA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-1-[(2r)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-sulfanylpropanoyl]pyrrolidine Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)CC1=CC=CC=C1 UGKLUDVFRIAEDG-JBRKIFEHSA-N 0.000 claims description 2
- QWKCNFCCXZHLNS-GMIRWQTLSA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-methylsulfanylbutanoyl]pyrrol Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 QWKCNFCCXZHLNS-GMIRWQTLSA-N 0.000 claims description 2
- ZRTQFGOXENLJNB-SXMXEBDWSA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]pyrrolidine-2-carbonyl Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)CC1=CC=CC=C1 ZRTQFGOXENLJNB-SXMXEBDWSA-N 0.000 claims description 2
- IIGKWRHCFOEMQY-BXXNOCLASA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]acetyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]a Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 IIGKWRHCFOEMQY-BXXNOCLASA-N 0.000 claims description 2
- DMHCDRKWXHFBKY-YTAGXALCSA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 DMHCDRKWXHFBKY-YTAGXALCSA-N 0.000 claims description 2
- ZEWLJLWJGKUOCE-UTALAWHWSA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-methylsulfanylbutano Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZEWLJLWJGKUOCE-UTALAWHWSA-N 0.000 claims description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 2
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 241000359271 Besnoitia Species 0.000 claims description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical class OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 2
- 125000003047 N-acetyl group Chemical group 0.000 claims description 2
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 150000003147 proline derivatives Chemical class 0.000 claims 3
- OUSYFDXGONIFSX-UHFFFAOYSA-N 2-sulfooxyprop-2-enoic acid Chemical compound OC(=O)C(=C)OS(O)(=O)=O OUSYFDXGONIFSX-UHFFFAOYSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 108010058068 tyrosyl-seryl-phenylalanyl-lysyl-aspartyl-methionyl-prolyl-N-methyleucyl-alanyl-arginine Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 85
- 241000699670 Mus sp. Species 0.000 description 38
- 102000004127 Cytokines Human genes 0.000 description 33
- 108090000695 Cytokines Proteins 0.000 description 33
- 244000045947 parasite Species 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 210000002540 macrophage Anatomy 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 241000282887 Suidae Species 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 210000001616 monocyte Anatomy 0.000 description 14
- -1 hydroxethylcellulose Polymers 0.000 description 13
- 241001529936 Murinae Species 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 210000004988 splenocyte Anatomy 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 208000031513 cyst Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 7
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000001589 lymphoproliferative effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000033289 adaptive immune response Effects 0.000 description 5
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 101100069385 Toxoplasma gondii GRA6 gene Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 208000012851 brain cyst Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000011577 humanized mouse model Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101100056797 Canis lupus familiaris SAG gene Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 101100532512 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SAG1 gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 241000223996 Toxoplasma Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000061 bradyzoite Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000000059 tachyzoite Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 101100122821 Toxoplasma gondii GRA3 gene Proteins 0.000 description 2
- 101100069387 Toxoplasma gondii GRA7 gene Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229950005134 polycarbophil Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 0 *[C@@]1OC(*)(*)N[C@]1C(O)=O Chemical compound *[C@@]1OC(*)(*)N[C@]1C(O)=O 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- WQMQRNCPZFUGID-UHFFFAOYSA-N 2-azaniumyladamantane-2-carboxylate Chemical compound C1C(C2)CC3CC1C(C(O)=O)(N)C2C3 WQMQRNCPZFUGID-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101710196690 Actin B Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 241000612703 Augusta Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- FYIPBNLUKZEKTA-UHFFFAOYSA-N CC(C)(CC1)NC1(C)C(O)=O Chemical compound CC(C)(CC1)NC1(C)C(O)=O FYIPBNLUKZEKTA-UHFFFAOYSA-N 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101150010973 GRA1 gene Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101100395310 Homo sapiens HLA-A gene Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000091577 Mexicana Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001314546 Microtis <orchid> Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 244000111261 Mucuna pruriens Species 0.000 description 1
- 235000006161 Mucuna pruriens Nutrition 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 241001147185 Oryzomys Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 101100069383 Toxoplasma gondii GRA5 gene Proteins 0.000 description 1
- 241000387654 Toxoplasma gondii ME49 Species 0.000 description 1
- 206010057179 Toxoplasma infections Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 159000000021 acetate salts Chemical group 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229960005008 doxylamine succinate Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical group OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- UZGLIIJVICEWHF-UHFFFAOYSA-N octogen Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 UZGLIIJVICEWHF-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/012—Coccidia antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A61K39/018—Babesia antigens, e.g. Theileria antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to anti-parasitic compounds comprising a peptide adjuvant conjugated to a parasitic peptide antigen.
- Toxoplasma gondii (T. gondii ) is an obligate intracellular protozoan parasite capable of infecting all warm-blooded animals, but cats are the only known definitive hosts in which the parasite undergoes sexual reproduction. In some cases of individuals with compromised or immature immune systems, infection causes severe neurological tissue degeneration and birth defects. However, the parasite typically produces no readily observable symptoms in healthy human adults, which may remain in an asymptomatic state of infection (aka latent infection) for life. It is estimated that a third of the world’s human population is chronically infected with this parasite. More recently, it has been proposed that even latent T. gondii infection is associated with numerous subtle adverse or pathological behavioral alterations in humans and other animals, including rodent models.
- T. gondii infection stimulates production of cytokines IL-2 and IFN-g by the innate immune system, which ultimately elicits a CD4+ and CD8+ T-cell mediated immune response, thereby preventing subsequent acute infections.
- T-cells play a central role in immunity against Toxoplasma infection.
- T-cells recognize Toxoplasma antigens that are presented to them by the body’s own Major Histocompatibility Complex (MHC) molecules.
- MHC Major Histocompatibility Complex
- the parasite To evade destruction by the immune system, the parasite ultimately converts to semi-dormant forms called bradyzoites, which cluster together to form tissue cysts.
- These tissue cysts can form in nearly any tissue, but are predominately deposited and persist in muscle and nervous tissue of the host, especially the brain, eyes, and striated muscle (including the heart).
- anti-parasitic compounds comprising a peptide adjuvant that is a response-selective C5aR agonist conjugated to a peptide antigen of a target parasite.
- the anti- parasitic compounds initiate cell-mediated immune responses required to protect against T gondii infection, as well as other parasitic infections.
- the anti-parasitic compounds are taken up by the target cells, the peptide antigen is cleaved, processed, and presented by the cell for immune cell recognition.
- the anti-parasitic compounds are useful for vaccines against T gondii infection, as well as other parasitic infections.
- Peptide epitopes/antigens suitable for use in the compounds include those demonstrated immunogenic MHC class I (with additional support for MHC II and/or B cell) epitopes in humans and/or mice.
- epitopes/antigens comprise an amino acid sequence fully conserved in Type I, II, and III strains of T gondii.
- epitopes/antigens can be derived from a parasite protein expressed in both the tachyzoite and bradyzoite stages and expressed in high levels (top 2/3 of all measured transcripts).
- embodiments described herein concern anti-parasitic compounds comprising an N- terminal peptide antigen conjugated to a C-terminal peptide adjuvant via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a (preferably a C5aR agonist), wherein the peptide antigen comprises an antigenic epitope of a parasitic organism.
- compositions comprising the such anti-parasitic compounds dispersed in a pharmaceutically acceptable carrier are also described herein.
- Embodiments of the invention also concern methods for therapeutic or prophylactic treatment of or induction of an immune response against a parasitic infection.
- the methods comprise administering anti-parasitic compound(s) according to various embodiments described herein to a subject in need thereof.
- the disclosure also concerns the use of anti-parasitic compound(s) according to various embodiments described herein to prepare a therapeutic or prophylactic medicament for inducing an immune response against parasitic infection in a subject.
- Figure (Fig.) 1 shows the structure of residue substitutions options for residue 7 in SEQ ID NO: 1, with name designations for preferred peptides;
- Fig. 2 shows additional residue substitutions for peptide analogs
- Fig. 3 shows EP67 (proline substitution at position 7) and additional alternative residue substitutions
- Fig. 4A show the results of exposure of human monocytes to analogs over the course of 6 and 24 hours;
- Fig. 4B show the results of exposure of human monocyte-derived dendritic cells to analogs over the course of 6 and 24 hours;
- Fig. 5 shows the immunophenotypes of human dendritic cells generated from peripheral blood monocytes as analyzed with flow cytometry
- Fig. 6 shows human monocytes (ca. 10 4 ) incubated 48 hrs in the presence of 50 pg/ml of scrambled sequence EP67 (Panel A) and EP67 (Panel B). 20X magnification;
- Fig. 7A shows a graph of cytokine release from human DCs incubated for 6 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me);
- Fig. 7B shows a graph of cytokine release from human macrophages (MC) incubated for 6 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me);
- Fig. 7C shows a graph of cytokine release from human DCs incubated for 24 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me);
- Fig. 7D shows a graph of cytokine release from human macrophages (MC) incubated for 24 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me);
- Fig. 8 shows Cytokine release from Balb/c splencoytes (left panel) and splenocytes obtained from aged sentinel mice (right panel) incubated with EP67 and scrambled EP67 (50 pg/ml) for 48 hours;
- Fig. 9 shows Murine dendritic cell activation following 6hr exposure to EP67 vaccines
- Fig. 10 increase surface activation markers of exposed dendritic cells following exposure to EP67 vaccines
- Fig. 11 shows recorded weights indicating a lack of toxicity in EP67-vaccinated mice
- Fig. 12 shows results from the lymphoproliferative assay indicating specific antigen response
- Fig. 13 A shows secretion of TNF-a in RAW 264.7 cells exposed to recombinant C5a and
- Fig. 13B shows secretion of IL-6 in RAW 264.7 cells exposed to recombinant C5a and
- Fig. 14 illustrates the mouse vaccination schedule for Figure 11 and 12;
- Fig. 15 is a graph of the Interferon Gamma ELISA results in the vaccinated mice models
- Fig. 16 is a graph of the survival curve for mice vaccinated and the challenged with T. gondii in the Examples;
- Fig. 17 is a graph demonstrating that the vaccine may prevent disease in humanized mice vaccinated in the Examples and challenged with T. gondii ;
- Fig. 18 is a graph of the results from the lymphoproliferative assay in the humanized mice vaccinated in the Examples;
- Fig. 19 is a graph of the brain cysts detected in mice vaccinated and the challenged with T. gondii in the Examples, showing a 28-fold decrease of cysts in 4 mice per group;
- Fig. 20 is a graph of ELISA on serum collected from pigs, showing T. gondii infection.
- the present invention is concerned with anti-parasitic compounds and methods for use in therapeutic or prophylactic treatment of parasitic infections, and specifically oligopeptide products capable of eliciting an immune response to a parasitic infection through selective activation of C5a receptor-bearing antigen presenting cells (e.g., macrophages, monocytes, dendritic cells, etc.) in the absence of triggering harmful inflammatory responses.
- C5a receptor-bearing antigen presenting cells e.g., macrophages, monocytes, dendritic cells, etc.
- the anti-parasitic compounds comprise C5aR agonist peptides that selectively bind C5a receptor-bearing antigen presenting cells without binding inflammatory granulocytes, to deliver antigenic moieties for cell presentation and stimulation of the immune response.
- the C5aR agonist peptides described in this invention can be used to selectively induce acquired immune responses when coupled with an immunogenic agent, which can then be targeted directly to antigen presenting cells through the specific binding of the agonist peptides.
- the C5aR agonist peptides are covalently linked to the immunogenic agent (optionally via a spacer moiety), whereby binding of the peptide to an antigen presenting cell C5a receptor activates the antigen presenting cell, effecting delivery of the immunogenic agent to an antigen presenting pathway of the antigen presenting cell.
- these agonists are useful as molecular vaccine adjuvants to enhance the efficacy and immune stimulating properties of parasitic vaccine compositions.
- Exemplary immunogenic agents for use in the anti-parasitic compounds are peptide antigens and specific peptide epitopes or other antigenic moieties derived from and conserved in the target parasite while avoiding homology to host protein sequences, such that administration of the anti-parasitic compound will provoke a selective immune response (e.g., CD8+ T-cell reactivity) in the host specific to the parasitic organism.
- the peptide antigen can be a human or non-human mammalian MHC class I- or class Il-restricted antigenic peptide.
- the peptide antigen may be“pre-restricted” and represent the antigenic epitope portion of the peptide.
- MHC class I restricted peptides are from 7-11 amino acids in length, while MCH class II restricted peptides are 10-14 amino acids in length.
- the peptide antigen conjugated to the peptide adjuvant may be a longer peptide sequence (e.g., ⁇ 20 mer), which is processed by the natural antigenic processing machinery of the cell, and thereafter presented on the antigen presenting cell.
- MHC -I molecules it is generally recognized that the requirement for binding and presentation by MHC -I molecules is one of the most selective events of antigen processing and presentation.
- preferred antigens will have a binding affinity for MHC-I.
- the selected peptide antigens may be species-specific, and in silico or other methods may be used to predict MHC-I affinity for the peptide epitopes to be synthesized and conjugated to the peptide adjuvants for selective delivery to the antigen presenting cells of a particular host.
- peptide antigens or epitope fragments may be synthesized that are species-agnostic (i.e., reaction across species).
- the peptide antigens are linear peptides of less than 16 amino acid residues, and preferably from about 9 to about 15 residues. Exemplary peptide antigens are described herein. Preferred vaccines are listed below that have been shown to work in animal models, including humanized models, as shown below conjugated to a peptide adjuvant, via a cleavable arginine linker:
- SAG1242-256 SFKDILPKLSENPWQ -RR- Y SFKDMP(MeL)aR (SEQ ID NO:25)
- GRA1 P2-186 EEVIDTMKSMQRDEE-RR-Y SFKDMP(MeL)aR (SEQ ID NO:26)
- AMAI41-55 CAELCDPSNKPGEfLL-RR-Y SFKDMP(MeL)aR (SEQ ID NO:27)
- GRA6210-224 DRRPLEfPGSVNEFDF-RR-Y SFKDMP(MeL)aR (SEQ ID NO:29)
- GRA714-28 GL VAAALPQFA TAA G-RR- Y SFKDMP(MeL)aR (SEQ ID NO: 30)
- Peptide adjuvants according to the invention are analogs of C5a, and particularly the C- terminal domain of C5a, and are designed to selectively bind C5aR-bearing macrophages (and other APCs) but not C5aR-bearing neutrophils.
- the present invention is particularly concerned with hydrochloride (HC1) salt forms of these peptide adjuvants, described in detail in co-pending WO 2018/231838, filed June 12, 2018, incorporated by reference in its entirety herein.
- HC1 hydrochloride
- These peptide adjuvants are linear peptides comprising less than 40 amino acid residues, preferably from 5 to 40 residues, more preferably from 5 to 20 residues, and even more preferably from 5 to 10 residues in length.
- the peptide adjuvant is a decapeptide (i.e., 10 amino acids in length).
- a preferred peptide adjuvant that is exemplified in the examples is designated as EP67. This peptide is described in detail in U.S. 2014/0314839, filed Nov. 30, 2012 and U.S. 2015/0297668, filed June 29, 201 1, incorporated by reference herein.
- the recently developed, biologically-compatible HC1 salt form of the bioactive peptide EP67 displays enhanced efficacy and quicker acquisition to maximum potency than the trifluoroacetate
- Conformationally-stable means that the peptide is generally fixed in a single geometric orientation/conformation/molecular arrangement and not prone to conversion/rotation to a different orientation. In other words, rotation of bonds (particularly between the cis and trans configurations) is restricted or eliminated in the conformationally-stable analogs. Individual residue may also have a“constrained conformation,” which means that they do not undergo cisltrans isomerization.
- Xaa is a modified proline residue or a residue substitution for proline
- Xaa2 is leucine or N-methyl leucine.
- the modified proline residue when used, is one that lacks the cisltrans isomerization of unmodified proline.
- these peptides have a fixed conformation and selective C5a receptor binding activity.
- exemplary peptide adjuvants include EP67 (where Xaa is P and Xaa2 is MeL, SEQ ID NO:2), EP144 (where Xaa is 2- aminoisobutyric acid and Xaa2 is L, SEQ ID NO:3), or EP145 (where Xaa is 5,5’-dimethylproline and Xaa2 is MeL, SEQ ID NO:4), which are depicted in Fig. 1.
- Other possible residue substitutions for the proline residue in EP7 are shown in Fig. 2, including 2-aminoadamantane-2- carboxylic acid, 2-azabicyclo[2. l .
- exemplary replacement residues for the proline residue of EP67 (Xaa) include alanine; leucine; isoleucine; N-methylalanine; 2-aminoisobutyric acid; 3- aminoisobutyric acid; N-methylisoleucine; singly-substituted proline analogs at the 2, 3, 4, and/or 5 positions of the pyrrolidine side chain; doubly-substituted proline analogs at the 2, 3, 4, and/or 5 positions of the pyrrolidine side chain; pseudoproline analogs: cysteine-derived thiazolidine, serine-derived oxazolidine, or threonine -derived oxazolidine; trifluoromethylated pseudoprolines; proline analog or homolog having a constrained conformation; trifluoromethylated azetidine 2- carboxylic acid; trifluoromethylated homoserine; oxetanyl-containing peptidomimetic; N- aminoimidazo
- Exemplary singly- or doubly-substituted substituted proline analogs include 5,5’-dimethylproline, 2,4-methano-P- proline, or 2,5-ethano-P-proline.
- Exemplary serine / threonine / cysteine-derived pseudoproline analogs are selected from the group consisting of:
- Exemplary N-aminoimidazolidin-2- one analogs are selected from the group consisting of N-amino-imidazolidinone, a-amino-g- lactam, and an azapeptide.
- C5a Additional C-terminal analogs of C5a are also contemplated herein for use as the peptide adjuvant in the antiparasitic compound, including those comprising, consisting essentially, or consisting of the formula:
- a 1 - Ser-Phe-Ly s- A2- A3 - A4- A5 - A6- A7 (SEQ ID NO:5) wherein: Al is Tyr, Trp, or N-acetyl derivatives of Tyr or Trp; A2 is Asp, Gly, Pro or N-methyl derivatives of Asp or Gly; A3 is Ala, Cys, Leu, Met or N-methyl derivatives of Ala, Cys, Leu or Met; A4 is Gln, Leu, Pro or N-methyl derivatives of Gln or Leu; A5 is Pro, Leu, a-methyl Leu or N-methyl Leu; A6 is D-Ala, Gly, D-Pro, aminoisobutyric acid (Aib) or N-methyl derivatives of D-Ala or Gly; and A7 is Arg or N-methyl Arg; such as peptides selected from the group consisting of:
- Tyr-Ser-Phe-Lys-Asp-Met-Gln-Pro-Gly-Arg SEQ ID NO: 15
- Tyr-Ser-Phe-Lys-Asp-Met-Pro-Leu-Aib-Arg SEQ ID NO: 16
- the anti-parasitic compound comprises (consists essentially or even consists of) the peptide antigen (or HC1 salt thereof) physically linked or conjugated to the peptide adjuvant, and more preferably conjugated to the amino-terminal end of the peptide adjuvant.
- the peptide antigen is linked to the peptide adjuvant by a cleavable linker, such as a protease-sensitive dipeptide or oligopeptide.
- the cleavable linker is sensitive to cleavage by a protease of the trypsin family of proteases.
- the cleavable linker comprises a dibasic dipeptide sequence, such as an Arg-Arg dipeptide sequence or a tetrapeptide Arg-Val-Arg-Arg (SEQ ID NO:78), and the like.
- Various cleavable linkers can be synthesized by those skilled in the art.
- the components of the anti-parasitic compound can be made separately, then conjugated, or can be synthesized in tandem by peptide synthetic chemistry according to known methods.
- compositions comprising the anti-parasitic compound are also described herein.
- the compositions may comprise a single type of anti-parasitic compound (monovalent), or may include a cocktail or mixture of more than one anti-parasitic compound according to the embodiments of the invention (multivalent).
- the composition could comprise two or more different peptide antigens, three or more different peptide antigens, four or more different peptide antigens, five or more different peptide antigens, even six or more different peptide antigens mixed together and administered as part of the same unit dosage form.
- the composition comprises a pharmaceutically acceptable carrier.
- carrier is used herein to refer to diluents, excipients, vehicles, coatings and the like, in which the peptide(s) may be dispersed or coated with for administration.
- Suitable carriers will be pharmaceutically acceptable.
- pharmaceutically acceptable means not biologically or otherwise undesirable, in that it can be administered to a subject without excessive toxicity, irritation, or allergic response, and does not cause unacceptable biological effects or interact in a deleterious manner with any of the other components of the composition in which it is contained.
- a pharmaceutically-acceptable carrier would naturally be selected to minimize any degradation of the compound or other agents and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
- compositions include those acceptable for veterinary use as well as human pharmaceutical use, and will depend on the route of administration. Any carrier compatible with the excipient(s) and the anti-parasitic compound can be used. Supplementary active compounds may also be incorporated into the compositions.
- a composition of the present disclosure is formulated to be compatible with its intended route of administration.
- routes of administration include oral administration (ingestion) and parenteral administration, e.g., intravenous, intradermal, subcutaneous, intraperitoneally, inhalation, nasal, transdermal (topical), transmucosal, buccal, sublingual, pulmonary and rectal administration.
- compositions suitable for injectable use include sterile aqueous solutions (where water-soluble), solutions in sterile isotonic aqueous buffer, or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, Cremophor ELTM (BASF, Parsippany, N.J.), bacteriostatic/sterile water/distilled autoclaved water (DAW), or phosphate buffered saline (PBS). In all cases, the composition is sterile and fluid to allow syringability.
- the carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Fluidity is maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition.
- Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
- the injectable preparations may be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
- Solutions or suspensions used for parenteral application may include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol, various oil-in-water or water-in-oil emulsions, as well as dimethyl sulfoxide (DMSO), or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH may be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- Oral compositions generally include an inert diluent or an edible carrier.
- Oral formulations generally take the form of a pill, tablet, capsule (e.g., soft gel capsule, solid-filled capsule, or liquid-filled capsule), solid lozenge, liquid-filled lozenge, mouth and/or throat drops or spray, effervescent tablets, orally disintegrating tablet, suspension, emulsion, syrup, elixir, or tincture.
- the composition may be contained in enteric forms to survive the stomach or further coated or mixed to be released in a particular region of the gastrointestinal tract by known methods. Solid oral dosage forms are typically swallowed immediately, or slowly dissolved in the mouth.
- Oral compositions may also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
- Oral formulations optionally contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; starch or lactose; a disintegrating agent such as alginic acid, PrimogelTM, or com starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; and/or a sweetening agent such as sucrose or saccharin.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- starch or lactose such as alginic acid, PrimogelTM, or com starch
- a lubricant such as magnesium stearate
- a glidant such as colloidal silicon dioxide
- a sweetening agent such
- the composition is optionally delivered in the form of a spray.
- the spray may be an aerosol spray from a pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- the composition is optionally formulated for delivery via a dry powder inhaler (DPI), a metered dose inhaler (pMDI), nasal spray, or a vaporizer.
- DPI dry powder inhaler
- pMDI metered dose inhaler
- nasal spray or a vaporizer.
- a penetrant for routes of administration involving absorption of an agent and/or excipient through mucosal membrane.
- the composition is formulated as a“liquid respiratory composition,” i.e., a composition in a form that is deliverable to a mammal via the oral cavity, mouth, throat, nasal passage or combinations thereof.
- a“liquid respiratory composition” i.e., a composition in a form that is deliverable to a mammal via the oral cavity, mouth, throat, nasal passage or combinations thereof.
- These compositions can be delivered by a delivery device selected from droppers, pump, sprayers, liquid dropper, spoon, cup, squeezable sachets, power shots, and other packaging and equipment, and combinations thereof.
- the liquid respiratory composition comprises the therapeutic agent, and excipient, a thickening polymer (e.g., xanthan gum, cellulosic polymers such as carboxymethylcellulose (CMC), hydroxethylcellulose, hydroxymethylcellulose, and hydroxypropylmethylcellulose, carrageenan, polyacrylic acid, cross-linked polyacrylic acid such as Carbopol®, polycarbophil, alginate, clay, and combinations thereof), and optionally a mucoadhesive polymer (e.g., polyvinylpyrrolidone (Povidone), methyl vinyl ether copolymer of maleic anhydride (Gantrez®), guar gum, gum tragacanth, polydextrose, cationic polymers, polyethylene oxide), poly(ethylene glycol), poly(vinyl alcohol), poly(acrylic acid), cross-linked polyacrylic acid such as Carbopol®, polycarbophil, poly(hydroxyl ethyl methacrylate), chito
- the composition is preferably a non- Newtonian liquid that exhibits zero shear viscosity from about 100 centiPoise (cP) to about 1,000,000 cP, from about 100 cP to about 500,000 cP, from about 100 cP to about 100,000 cP, from about 100 cP to about 50,000 cP, from about 200 cP to about 20,000 cP, from about 1,000 to about 10,000 cP at a temperature of about 37 °C, as measured according to the Shear Viscosity Method.
- the pH range of the formulation is generally from about 1 to about 7, from about 2 to about 6.5, and from about 4 to about 6.
- additional pharmaceutically-acceptable ingredients for use in the compositions include buffering agents, salts, stabilizing agents, diluents, preservatives, antibiotics, isotonic agents, cell media (e.g., MEM, FBS), flavoring agents, and the like.
- exemplary isotonic agents include dextrose, lactose, sugar alcohols (e.g., sorbitol, mannitol), and the like.
- Stabilizing agents include sugars such as sucrose and lactose, amino acids such as glycine or the monosodium salt of glutamic acid and proteins such as albumin or gelatin, and mixtures thereof.
- Exemplary preservatives include formaldehyde, thimerosal, and the like.
- a nasal spray formulation may comprise benzalkonium chloride, camphor, chlorhexidine gluconate, citric acid, disodium EDTA, eucalyptol, menthol, purified water, and/or tyloxapol.
- An exemplary oral composition may comprise FD&C Blue No. 1, gelatin, glycerin, polyethylene glycol, povidone, propylene glycol, purified water, sorbitol special, and/or titanium dioxide in addition to an excipient and acetaminophen, doxylamine succinate, and phenylephrine HC1 (or dextromethorphan) .
- Unit dosage form refers to physically discrete units suited as unitary dosages for the subject to be treated, each unit containing a predetermined quantity of the anti-parasitic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms are dictated by and are directly dependent on the unique characteristics of the excipient(s) and therapeutic agent(s) and the particular biological effect to be achieved.
- compositions described herein are determined by standard procedures using in vitro or in vivo technologies, such as the materials and methods described herein and/or known in the art.
- Administration may be on an as-needed or as-desired basis, for example, once-monthly, once-weekly, or daily, including multiple times daily, for example, at least once daily, from one to about ten times daily, from about two to about four times daily, or about three times daily.
- a dose of composition optionally comprises about from about 0.001 mg to about 1000 mg active agent, alternatively from about 2.5 mg to about 750 mg active agent, and alternatively from about 5 mg to about 650 mg of the active agent.
- a dose of composition according to the present disclosure comprises about from 0.1 mg to about 0.25 mg.
- a dose of composition according to the present disclosure comprises 25 pg, 50 pg, 60 pg, 70 pg, 80 pg, 90 pg, 100 pg, 125 pg, 150 pg, 175 pg, 200 pg, 225 pg, 250 pg, 275 pg, 300 pg, 325 pg, 350 pg, 375 pg, 400 pg, 425 pg, 450 pg, 475 pg or 500 pg.
- a dose of composition according to the present disclosure comprises between 25 pg to 500 pg, 50 pg to 400 pg, 100 pg to 300 pg, or 200 pg to 250 pg.
- compositions used according to the invention comprise a plurality of anti-parasitic compounds, and specifically different anti-parasitic compounds, each comprising a different peptide antigen.
- Such“cocktail” compositions can be useful to deliver multiple different peptide antigens each conjugated to a peptide adjuvant, and initiate a more robust immune response.
- the same peptide adjuvant can be used in the composition across the different types of peptide antigens.
- different peptide adjuvants can be used for different types of peptide antigens.
- the compositions may be formulated with different antigens to target different types of parasites (i.e., broad spectrum or“cocktail”).
- the composition may be formulated with different antigens that are nonetheless specific to one particular target parasite.
- the target parasite is a protozoan, and particularly a pathogenic protozoan that causes infection in humans or animals.
- exemplary target parasites are protozoans, including, without limitation, Entamoeba histolytica, Eimeria spp.
- Theileria spp. parva, annulata, orientalis, velifera, taurotragi, sergenti, lestoquardi, mutans, hirci, ovis , etc.
- a therapeutically-effective amount of the anti-parasitic compound is administered to a subject in need thereof.
- Administration of the anti-parasitic compound elicits an immune response in the subject, and more specifically a selective activation of the innate immune response, without direct activation of pro-inflammatory neutrophils and other granulocytes.
- the immune response will be demonstrated by a lack of observable clinical symptoms, or reduction of clinical symptoms normally displayed by an infected subject, faster recovery times from infection, reduced duration of infection, and the like.
- a method of activating an immune cell at a site of infection or disease comprising administering an effective amount of the anti-parasitic compound to a mammal, wherein the anti-parasitic compound has selective C5a receptor binding activity for targeted delivery and uptake of the peptide antigen.
- the anti-parasitic compound does not directly bind or activate the pro- inflammatory granulocytes, a secondary inflammatory response may be initiated due to the release of chemokines/cytokines by the APCs once activated by the anti-parasitic compound.
- kits comprising the anti-parasitic compound is also disclosed herein.
- the kit further comprises instructions for administering the anti-parasitic compound to a subject.
- the anti- parasitic compound can be provided as part of a dosage unit, already dispersed in a pharmaceutically-acceptable carrier, or it can be provided separately from the carrier.
- the kit can further comprise instructions for preparing the anti-parasitic compound for administration to a subject, including for example, instructions for dispersing the anti-parasitic compound in a suitable carrier.
- therapeutic and prophylactic methods described herein are applicable to humans as well as any suitable warm-blooded animal, including, without limitation, dogs, cats, and other companion animals, as well as, rodents, primates, horses, cattle, sheep, pigs, etc.
- the methods can be also applied for clinical research and/or study.
- the term “treating” or “treatment” refers to an intervention performed with the intention of preventing the development or altering the pathology of infection. Accordingly,“treatment” refers to both therapeutic treatment and prophylactic or preventative measures.
- a therapeutic agent may directly decrease the pathology of infection, or render the infection more susceptible to treatment by other therapeutic agents or, for example, the host’s immune system. Improvement after treatment may be manifested as a decrease or elimination of such symptoms.
- the compositions are useful in treating a the infection by preventing the development of observable clinical symptoms from infection, and/or reducing the incidence or severity of clinical symptoms and/or effects of the infection, and/or reducing the duration of the infection/symptoms/effects.
- the phrase“effective amount” or“therapeutically effective amount” is meant to refer to a therapeutic or prophylactic amount of the anti-parasitic compound or its antigenic peptide that would be appropriate for an embodiment of the present disclosure, that will elicit the desired therapeutic or prophylactic effect or response, including alleviating some or all of such symptoms of infection or reducing the predisposition to the infection, when administered in accordance with the desired treatment regimen.
- an amount may be considered therapeutically“effective” even if the condition is not totally eradicated or prevented, but it or its symptoms and/or effects are improved or alleviated partially in the subject.
- the therapeutically effective dosage of anti-parasitic compound or its antigenic peptide may vary depending on the size and species of the subject, and according to the mode of administration.
- the phrase "and/or," when used in a list of two or more items, means that any one of the listed items can be employed by itself or any combination of two or more of the listed items can be employed.
- the composition can contain or exclude A alone; B alone; C alone; A and B in combination; A and C in combination; B and C in combination; or A, B, and C in combination.
- the present description also uses numerical ranges to quantify certain parameters relating to various embodiments of the invention. It should be understood that when numerical ranges are provided, such ranges are to be construed as providing literal support for claim limitations that only recite the lower value of the range as well as claim limitations that only recite the upper value of the range. For example, a disclosed numerical range of about 10 to about 100 provides literal support for a claim reciting "greater than about 10" (with no upper bounds) and a claim reciting "less than about 100" (with no lower bounds).
- Criteria for selecting antigenic peptides to include in the vaccine with the C5aR agonist peptide include:
- -Epitope is derived from a parasite protein expressed in tachyzoite and bradyzoite stage -Computer predicted immunogenicity of MHC class I epitope in B ALB/c haplotype -Epitope is derived from a parasite protein expressed at the top 2/3rds of abundant transcripts
- -Epitope is derived from a parasite protein expressed on the surface or during invasion
- Peptides were synthesized with the following antigenic sequences for Toxoplasma gondii , and conjugated to either EP67 or a scrambled EP67 sequence (as a control).
- HLA peptides include: VVFVVFMGV (GRA6; SEQ ID NO:37); FMGVLVNSL (GRA6; SEQ ID NO: 38); FLVPFVVFL (GRA3; SEQ ID NO: 39); KSFKDILPK (SAG1; SEQ ID NO:40); AMLTAFFLR (GRA6; SEQ ID NO:4l); RSFKDLLKK (GRA7; SEQ ID NO:42); LPQFATAAT (GRA7; SEQ ID NO:43); VPFVVFLVA (GRA3; SEQ ID NO:44); HPGSVNEFDF (GRA6; SEQ ID NO:45); STFWPCLLR (SAG2C 13-21; SEQ ID NO:46); AVVSLLRLLK (SPA/GRA5 89-98; SEQ ID NO:47); and SSAYVFSVK (SRS52A 250-258; SEQ ID NO:48).
- Other HLA-A*0201 candidates include:
- Vaccine 1 SAGI242-256 (SEQ ID NO: 25); Vaccine 2: GRAlm-ise (SEQ ID NO: 26); Vaccine 3: AMAHi-ss (SEQ ID NO: 27); Vaccine 4: SAG3208-222 (SEQ ID NO: 28); Vaccine 5: GRA6210-224 (SEQ ID NO: 29); Vaccine 6: GRA7I 4 -28 (SEQ ID NO: 30).
- the peptides were an unexpected synthetic challenge, but were ultimately synthesized for testing.
- Vaccines were purified with analytical and preparative HPLC and characterized with electrospray mass spectrometry:
- Inactive vaccines were also constructed, either with scrambled EP67 or the reverse orientation constructs (with EP67 at the N-terminal end, e.g., EP67-RR-epitope), as negative controls using“inactive” constructs that have the same amino acid composition as the“active” EP67-based vaccines. Synthesis, purification, and characterization was carried out of the T. gondii epitopes and the biologically inert vaccines; i.e., the reverse orientation constructs (EP67 on the N-terminal side and the epitope on the C-terminal side) and the normal orientation constructs, but with scrambled sequence EP67 on the C-terminal side.
- Free EP67 (unattached to any epitope) was used as a control to stimulate murine bone marrow-derived dendritic cells (See Table 1 below). Preliminary data show that EP67 is capable of inducing all four cytokines initially evaluated: IL-10, CXCL1, TNF-alpha, and IL-6. Testing these and additional cytokines (at the gene and protein-expression levels) against all of the synthesized and control vaccines is carried out. Similarly, we will also be analyzing surface marker expression indicative of DC activation.
- EP67 50 pg/ml was incubated with bone marrow-derived mouse dendritic cells (24 hrs) following in vitro maturation. Fold changes in expression were compared to PBS controls and normalized to Actin B gene expression. Three replicates were analyzed per gene. The results show that EP67, compared to PBS controls, caused increased expression of IL-10, CXCL1, TNF- alpha and IL-6. A positive control, bacterial LPS, was also evaluated and produced upregulation of at least 20-fold above PBS controls for all evaluated cytokines. EXAMPLE 4
- the HC1 salt forms of our peptides were generated by mixing the peptide in a water slurry with the strong anion exchange resin Amberlite IRA-400 Cl for a few hours. While this was effective in removing most of the TFA counter anions, it was not 100% effective (as indicated by 19 F-NMR). Also, the anion exchange resin gave a slight color change to the otherwise white peptide along with a fair amount of micro resin particles that required filtration. Once removed, the peptide in aqueous solution needed to be re-lyophilized to the dry powder. This desalting, filtering, and lyophilizing process was time consuming and added the possibilities of introducing impurities to the final product.
- Amberlite IRA-400 Cl Amberlite IRA-400 Cl
- Another approach is an improved single-step method for generating the HC1 salt forms of the above vaccines. This was accomplished by first eliminating the use of TFA in our HPLC purification. In place of 0.1% TFA we used 2% trimethylamine/phosphoric acid buffer, which we found to be an excellent buffer system particularly at the high flow rates we use on our preparative column for final purification of the crude peptide. Under these conditions, the phosphate salt of the peptide is generated, but it is easily exchanged with the HC1 salt by loading the peptide onto the same preparative column equilibrated with 5mM HC1 and bringing it off with a rapid gradient of acetonitrile. This method of purification and desalting is now our standard operating procedure for all peptides generated in our laboratory.
- HPLC chromatograms of each epitope and EP67-based vaccine were analyzed.
- HPLCs were run on Cis-bonded silica reverse-phase columns equilibrated with 0.5% trimethylamine (v/v) and 0.5% phosphoric acid (v/v) (TEAP buffer pH 2.3 - solvent system A) and peptides eluted with an increasing gradient of 60% acetonitrile in TEAP (solvent system B).
- Analytical flow rates were 1.5 mL/min and preparative flow rates were 60 mL/min. In both analytical and preparative modes, peptide separations were monitored at 214 nm.
- HC1 salt forms of these peptides were generated by loading the peptide collected from the TEAP preparative run onto the same preparative column, but equilibrated with 5 mM HC1 and brought off the column with a gradient of acetonitrile (0 - 50%) of acetonitrile over 5 minutes.
- Analytical flow rates were 1.5 mL/min and preparative flow rates were 60 mL/min. In both analytical and preparative modes, peptide separations were monitored at 214 nm.
- FIG. 5 shows the immunophenotypes of human dendritic cells generated from peripheral blood monocytes as analyzed with flow cytometry.
- Human peripheral blood monocytes obtained from the elutriation core facility at the University of Kansas Medical Center
- IL- 4 400 U/ml
- GM-CSF 800 U/ml
- the resulting cells expressed high levels of surface markers CD80, CD83, CD86, HLA-ABC, HLA-DR characteristic of DCs.
- EP67 Differentiates Human Peripheral Blood Monocytes to Cells with Phenotypes Characteristic of Macrophages/DCs.
- EP67 but not scrambled EP67, converts rounded and non- adhered monocytes into elongated, adhered cells that display spindle-like features characteristic of macrophages/DCs.
- Fig. 6 shows human monocytes (ca. 10 4 ) incubated 48 hrs in the presence of 50 pg/ml of scrambled sequence EP67 (Panel A) and EP67 (Panel B).
- EP67 Differentiates Human Peripheral Blood Monocytes to Cells with Immunophenotypes Characteristic of Macrophages/DCs. Human monocytes were incubated with EP67 (50 pg/ml) and surface markers analyzed over the course of 7 days. The data shows that EP67 moderately enhanced the expression of CD14, CD16, CDl lb, and CD33, but significanlty enhanced the expression of CD80 and CD206, which are characteristic of macrophages and DCs.
- EP67 Induces Cytokine Release from Human Macrophages and DCs (Fig. 7). Human monocyte-derived macrophages and DCs were incubated with EP67 (50 pg/ml) and scrambled EP67 (50 pg/ml) for 6 and 24 hours. Supernatants were collected and analyzed for the presence of the following cytokines: IL-lbeta, IL-2, IL-4, IL-6, IL-10, IL-l2p70, IL-13, IL-15, TNF-alpha, and IFN-gamma. Fig.
- cytokines relased at 6 and 24 hours in response to EP67 represent a THl/pro-inflammatory bias relative to the TH2/anti- inflammatory cytokines (IL-4, IL-5, IL-10, and IL-13).
- This THI bias is in keeping with earlier observations with EP67 and is an important immunologic component for an effective immune response to T. gondii.
- Splencocytes were obtained from normal Balb/c mice (ca. 2 months) and aged (ca. 17 months) sentinel mice of undetermined backgroud (a gift from the University of Kansas Medical Center Animal Facility). Spelocytes were cultured in the presence of EP67 and scrambled EP67 (50 pg/ml) for 24 hours, supernatants harvested, and analyzed for the presence of IL-lbeta, IL-2, IL-4, IL-5, IL-6, KC/GRO, IL-10, IL-l2p70, TNF-alpha, and IFN-gamma.
- Fig. 8 Splencocytes were obtained from normal Balb/c mice (ca. 2 months) and aged (ca. 17 months) sentinel mice of undetermined backgroud (a gift from the University of Kansas Medical Center Animal Facility). Spelocytes were cultured in the presence of EP67 and scrambled EP67 (50 pg/ml) for 24 hours, supernatants harvested, and
- FIG. 9 shows murine dendritic cell activation following 6hr exposure to EP67 vaccines.
- Bone marrow-derived BALB/c DCs were separately exposed to EP67- containing vaccines #1 (TgSAGl) and #2 (TgGRAl) (Example 3), and compared to sham exposure (media).
- the results were promising for the two vaccines that we tested (Fig. 9) in that exposure led to cytokine release above the controls, but only KC/GRO achieved at least an 80% increase compared to sham (our criteria for active vaccines).
- KC/GRO also known as CXCL1
- CXCL1 is a potent neutrophil chemotactic cytokine. Increases in INF-gamma, IL-lb, and TNF-a were also observed, and are in-line with expectations of EP67 engagement of the C5a receptor and subsequent activation of dendritic cells.
- EP76-containing vaccines were investigated and found to increase surface activation markers of exposed white blood cells, such as DCs shown in Fig. 10, which were exposed for 6 hours to Vaccines #1 (TgSAGl) and #2 (TgGRAl). Following exposure, cells were fixed and stained with antibodies to measure cell surface markers of intact cells by flow cytometry. Increases were observed in key markers of activation, including a sizeable increase (passing the required threshold of 80% increase) in CD80 from EP67 vaccine #2. Elevation occurred in CD80, CCR7, and MHC Class II molecules, indicating activation of dendritic cells compared to control (media only). As noted previously, human in vitro experiments suggest that EP67 containing vaccines more strongly activate macrophages following a six hour exposure.
- Fig. 12 demonstrates that mice were specifically reactive to antigens when previously vaccinated with EP67-containing vaccines.
- Fig. 12 shows results from the lymphoproliferative assay indicating specific antigen response.
- Figs. 13 A and 13B show the results of RAW 264.7 cells activated by EP67.
- RAW 264.7 were tested for secretion of TNF-a and IL-6.
- Fig. 15 demonstrates that the potent Thl- inducing interferon-gamma cytokine is released at significantly greater levels (p ⁇ 0.0l) when exposed to vaccinated antigen peptide vs splenocytes from control-treated mice. This indicates that EP67 vaccines can generate a specific, robust immune response against foreign peptides when vaccinated in this manner.
- Vaccination with EP67 Vaccines Prevented Mouse Death Following Acute Infection Mice were infected with 5,000 ME49 T. gondii parasites intraperitoneally following 3 rounds of vaccine treatment.
- a Student’s t test of difference between PBS and Hexavalent EP67 vaccine intraperitoneal administration yielded a p-value of 0.08, indicating a strong likelihood of protection from EP67- containing vaccines.
- the recombinant parasite protein SAG1 co-administered with EP67 did not elicit any immune protection.
- ME49 parasite lysate was administered in conjunction with Thl -stimulating CpG DNA.
- Fig. 18 demonstrates an adaptive immune response in the vaccinated mice.
- Vaccine Prevented Parasite Encystment in Humanized Mice
- Humanized mice (containing a human MHC locus) received 4 vaccine administrations, or PBS as a No Vaccine control, and challenged 15 days with T. gondii following the final vaccination. 21 days post-infection, surviving mice were sacrificed and brains removed to ascertain brain parasite cyst loads via qPCR detection. Parasite cyst loads, relative to brain DNA in each sample, was calculated and showed at least a 28-fold decrease in cysts, with the potential for no cysts in the brain.
- a Students t test showed a p value of 0.01 between vaccinated and unvaccinated animals (Fig. 19). This data indicates that EP67 vaccines were able to substantially reduce brain tissue cysts in the brains of vaccinated and infected mice which contain elements of human adaptive immunity compared to sham-treated mice.
- the anti-parasitic vaccines can generate specific splenic immune responses against l5mer antigens.
- the anti-parasitic vaccines significantly reduce brain cysts w / p-value ⁇ 0.0l .
- Vaccines are prepared as described above. Vaccine sequences may be sequence optimized for pigs and synthesized accordingly. Pigs are first screened and identified as potential carriers of the parasite. Pig sera was received. ELISA plates coated with T. gondii soluble lysate were rinsed and soaked overnight with provided sera. After rinsing, goat anti-pig IgG labeled antibodies were added followed by a final rinse and HRP activation and absorbance reading. The sera were run in two separate replicate experiments, with identical results. Mouse positive and negative controls were used. Generally (in mice serology) an absorbance reading below 0.5 is considered negative. Between 0.5 and 1 is considered potentially positive. And above 1.0 is considered positive. As shown in Fig. 20, several of the pig sera contained IgG antibodies against T. gondii , although #32 and #34 would be considered negative.
- PBS Phosphate buffered saline
- Pigs screened and identified to have a high parasite burden will receive a total of up to 10 mg vaccine/peptide per dose in 3 doses every 15 days (e.g., days 0, 15, and 30). Each pig will be weighed and observed daily to identify any apparent toxicity. Two pigs from each group will be sacrificed and the spleen harvested to evaluate lymphoproliferative properties when mesh- purified and separately splenocytes are exposed to 50 pg/mL total parasite lysate (positively controlled by concanavalin A). Cell-free supernatants from this exposure will be probed via ELISA for secretion of IFN-gamma, considered vital in preventing Toxoplasma-induced acute disease following infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Anti-parasitic compounds and uses thereof. Compounds comprising a C -terminal peptide adjuvant conjugated to an N-terminal peptide antigen via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism, such as T. gondii. Methods of therapeutic or prophylactic treatment of a parasitic infections.
Description
ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONS
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the priority benefit of U.S. Provisional Patent Application Serial No. 62/731,353, filed September 14, 2018, entitled ANTI-PARASITIC
IMMUNOLOGICAL COMPOSITIONS, incorporated by reference in its entirety herein.
FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
This invention was made with government support under contract #HHSN27220l 600038C awarded by the National Institutes of Health. The government has certain rights in the invention.
SEQUENCE LISTING
The following application contains a sequence listing in computer readable format (CRF), submitted as a text file in ASCII format entitled "Sequence_Listing_5l054-PCT," created on September 12, 2019, as 21 KB. The content of the CRF is hereby incorporated by reference.
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to anti-parasitic compounds comprising a peptide adjuvant conjugated to a parasitic peptide antigen.
Description of Related Art
Toxoplasma gondii (T. gondii ) is an obligate intracellular protozoan parasite capable of infecting all warm-blooded animals, but cats are the only known definitive hosts in which the parasite undergoes sexual reproduction. In some cases of individuals with compromised or immature immune systems, infection causes severe neurological tissue degeneration and birth defects. However, the parasite typically produces no readily observable symptoms in healthy human adults, which may remain in an asymptomatic state of infection (aka latent infection) for life. It is estimated that a third of the world’s human population is chronically infected with this parasite. More recently, it has been proposed that even latent T. gondii infection is associated with numerous subtle adverse or pathological behavioral alterations in humans and other animals, including rodent models. For example, studies have demonstrated that rodents infected with T. gondii have impaired motor performance. More recent personality studies on humans testing
positive for T. gondii infection indicated that infected men were more likely to disregard rules and were more expedient, suspicious, jealous, and dogmatic.
T. gondii infection stimulates production of cytokines IL-2 and IFN-g by the innate immune system, which ultimately elicits a CD4+ and CD8+ T-cell mediated immune response, thereby preventing subsequent acute infections. Thus, T-cells play a central role in immunity against Toxoplasma infection. T-cells recognize Toxoplasma antigens that are presented to them by the body’s own Major Histocompatibility Complex (MHC) molecules. To evade destruction by the immune system, the parasite ultimately converts to semi-dormant forms called bradyzoites, which cluster together to form tissue cysts. These tissue cysts can form in nearly any tissue, but are predominately deposited and persist in muscle and nervous tissue of the host, especially the brain, eyes, and striated muscle (including the heart).
Consumption of tissue cysts in raw or undercooked meat is one of the primary vectors of T gondii infection, both for humans and other meat-eating, warm-blooded animals. There is currently no human vaccine against T gondii infection. This lack of a vaccine can be traced, in large part, to the lack of vaccine adjuvant capable of generating the necessary immune requirements for effective protection.
SUMMARY OF THE INVENTION
Described herein are anti-parasitic compounds comprising a peptide adjuvant that is a response-selective C5aR agonist conjugated to a peptide antigen of a target parasite. The anti- parasitic compounds initiate cell-mediated immune responses required to protect against T gondii infection, as well as other parasitic infections. The anti-parasitic compounds are taken up by the target cells, the peptide antigen is cleaved, processed, and presented by the cell for immune cell recognition. The anti-parasitic compounds are useful for vaccines against T gondii infection, as well as other parasitic infections. Peptide epitopes/antigens suitable for use in the compounds include those demonstrated immunogenic MHC class I (with additional support for MHC II and/or B cell) epitopes in humans and/or mice. Preferably, such epitopes/antigens comprise an amino acid sequence fully conserved in Type I, II, and III strains of T gondii. More preferably, such epitopes/antigens can be derived from a parasite protein expressed in both the tachyzoite and bradyzoite stages and expressed in high levels (top 2/3 of all measured transcripts).
Thus, embodiments described herein concern anti-parasitic compounds comprising an N- terminal peptide antigen conjugated to a C-terminal peptide adjuvant via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a (preferably a C5aR agonist),
wherein the peptide antigen comprises an antigenic epitope of a parasitic organism. Compositions comprising the such anti-parasitic compounds dispersed in a pharmaceutically acceptable carrier are also described herein.
Embodiments of the invention also concern methods for therapeutic or prophylactic treatment of or induction of an immune response against a parasitic infection. The methods comprise administering anti-parasitic compound(s) according to various embodiments described herein to a subject in need thereof. The disclosure also concerns the use of anti-parasitic compound(s) according to various embodiments described herein to prepare a therapeutic or prophylactic medicament for inducing an immune response against parasitic infection in a subject.
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Figure (Fig.) 1 shows the structure of residue substitutions options for residue 7 in SEQ ID NO: 1, with name designations for preferred peptides;
Fig. 2 shows additional residue substitutions for peptide analogs;
Fig. 3 shows EP67 (proline substitution at position 7) and additional alternative residue substitutions;
Fig. 4A show the results of exposure of human monocytes to analogs over the course of 6 and 24 hours;
Fig. 4B show the results of exposure of human monocyte-derived dendritic cells to analogs over the course of 6 and 24 hours;
Fig. 5 shows the immunophenotypes of human dendritic cells generated from peripheral blood monocytes as analyzed with flow cytometry;
Fig. 6 shows human monocytes (ca. 104) incubated 48 hrs in the presence of 50 pg/ml of scrambled sequence EP67 (Panel A) and EP67 (Panel B). 20X magnification;
Fig. 7A shows a graph of cytokine release from human DCs incubated for 6 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me);
Fig. 7B shows a graph of cytokine release from human macrophages (MC) incubated for 6 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me);
Fig. 7C shows a graph of cytokine release from human DCs incubated for 24 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me);
Fig. 7D shows a graph of cytokine release from human macrophages (MC) incubated for 24 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me);
Fig. 8 shows Cytokine release from Balb/c splencoytes (left panel) and splenocytes obtained from aged sentinel mice (right panel) incubated with EP67 and scrambled EP67 (50 pg/ml) for 48 hours;
Fig. 9 shows Murine dendritic cell activation following 6hr exposure to EP67 vaccines;
Fig. 10 increase surface activation markers of exposed dendritic cells following exposure to EP67 vaccines;
Fig. 11 shows recorded weights indicating a lack of toxicity in EP67-vaccinated mice;
Fig. 12 shows results from the lymphoproliferative assay indicating specific antigen response;
Fig. 13 A shows secretion of TNF-a in RAW 264.7 cells exposed to recombinant C5a and
EP67;
Fig. 13B shows secretion of IL-6 in RAW 264.7 cells exposed to recombinant C5a and
EP67;
Fig. 14 illustrates the mouse vaccination schedule for Figure 11 and 12;
Fig. 15 is a graph of the Interferon Gamma ELISA results in the vaccinated mice models;
Fig. 16 is a graph of the survival curve for mice vaccinated and the challenged with T. gondii in the Examples;
Fig. 17 is a graph demonstrating that the vaccine may prevent disease in humanized mice vaccinated in the Examples and challenged with T. gondii ;
Fig. 18 is a graph of the results from the lymphoproliferative assay in the humanized mice vaccinated in the Examples;
Fig. 19 is a graph of the brain cysts detected in mice vaccinated and the challenged with T. gondii in the Examples, showing a 28-fold decrease of cysts in 4 mice per group; and
Fig. 20 is a graph of ELISA on serum collected from pigs, showing T. gondii infection.
DETAILED DESCRIPTION
The present invention is concerned with anti-parasitic compounds and methods for use in therapeutic or prophylactic treatment of parasitic infections, and specifically oligopeptide products capable of eliciting an immune response to a parasitic infection through selective activation of C5a receptor-bearing antigen presenting cells (e.g., macrophages, monocytes, dendritic cells, etc.) in the absence of triggering harmful inflammatory responses. The anti-parasitic compounds
comprise C5aR agonist peptides that selectively bind C5a receptor-bearing antigen presenting cells without binding inflammatory granulocytes, to deliver antigenic moieties for cell presentation and stimulation of the immune response.
The C5aR agonist peptides described in this invention can be used to selectively induce acquired immune responses when coupled with an immunogenic agent, which can then be targeted directly to antigen presenting cells through the specific binding of the agonist peptides. In one or more embodiments, the C5aR agonist peptides are covalently linked to the immunogenic agent (optionally via a spacer moiety), whereby binding of the peptide to an antigen presenting cell C5a receptor activates the antigen presenting cell, effecting delivery of the immunogenic agent to an antigen presenting pathway of the antigen presenting cell. Thus, these agonists are useful as molecular vaccine adjuvants to enhance the efficacy and immune stimulating properties of parasitic vaccine compositions.
Exemplary immunogenic agents for use in the anti-parasitic compounds are peptide antigens and specific peptide epitopes or other antigenic moieties derived from and conserved in the target parasite while avoiding homology to host protein sequences, such that administration of the anti-parasitic compound will provoke a selective immune response (e.g., CD8+ T-cell reactivity) in the host specific to the parasitic organism. Thus, the peptide antigen can be a human or non-human mammalian MHC class I- or class Il-restricted antigenic peptide. In other words, the peptide antigen may be“pre-restricted” and represent the antigenic epitope portion of the peptide. In general, MHC class I restricted peptides are from 7-11 amino acids in length, while MCH class II restricted peptides are 10-14 amino acids in length. Alternatively, the peptide antigen conjugated to the peptide adjuvant may be a longer peptide sequence (e.g., ~20 mer), which is processed by the natural antigenic processing machinery of the cell, and thereafter presented on the antigen presenting cell.
It is generally recognized that the requirement for binding and presentation by MHC -I molecules is one of the most selective events of antigen processing and presentation. In one or more embodiments, preferred antigens will have a binding affinity for MHC-I. It will be appreciated that the selected peptide antigens may be species-specific, and in silico or other methods may be used to predict MHC-I affinity for the peptide epitopes to be synthesized and conjugated to the peptide adjuvants for selective delivery to the antigen presenting cells of a particular host. In one or more embodiments, peptide antigens or epitope fragments may be synthesized that are species-agnostic (i.e., reaction across species).
In one or more embodiments, the peptide antigens are linear peptides of less than 16 amino
acid residues, and preferably from about 9 to about 15 residues. Exemplary peptide antigens are described herein. Preferred vaccines are listed below that have been shown to work in animal models, including humanized models, as shown below conjugated to a peptide adjuvant, via a cleavable arginine linker:
Name Sequence _
1. SAG1242-256 : SFKDILPKLSENPWQ -RR- Y SFKDMP(MeL)aR (SEQ ID NO:25)
2. GRA1 P2-186: EEVIDTMKSMQRDEE-RR-Y SFKDMP(MeL)aR (SEQ ID NO:26)
3. AMAI41-55: CAELCDPSNKPGEfLL-RR-Y SFKDMP(MeL)aR (SEQ ID NO:27)
4. SAG3208-222 KR VTCGYPESGPVNL-KR-Y SFKDMP(MeL)aR (SEQ ID NO:28)
5. GRA6210-224: DRRPLEfPGSVNEFDF-RR-Y SFKDMP(MeL)aR (SEQ ID NO:29)
6. GRA714-28: GL VAAALPQFA TAA G-RR- Y SFKDMP(MeL)aR (SEQ ID NO: 30)
Peptide adjuvants according to the invention are analogs of C5a, and particularly the C- terminal domain of C5a, and are designed to selectively bind C5aR-bearing macrophages (and other APCs) but not C5aR-bearing neutrophils. In particularly preferred embodiments, the present invention is particularly concerned with hydrochloride (HC1) salt forms of these peptide adjuvants, described in detail in co-pending WO 2018/231838, filed June 12, 2018, incorporated by reference in its entirety herein. These peptide adjuvants are linear peptides comprising less than 40 amino acid residues, preferably from 5 to 40 residues, more preferably from 5 to 20 residues, and even more preferably from 5 to 10 residues in length. In one or more embodiments, the peptide adjuvant is a decapeptide (i.e., 10 amino acids in length). A preferred peptide adjuvant that is exemplified in the examples is designated as EP67. This peptide is described in detail in U.S. 2014/0314839, filed Nov. 30, 2012 and U.S. 2015/0297668, filed June 29, 201 1, incorporated by reference herein. The recently developed, biologically-compatible HC1 salt form of the bioactive peptide EP67 displays enhanced efficacy and quicker acquisition to maximum potency than the trifluoroacetate
(TFA) and acetate salt forms. HC1 salt forms of conformationally-stable analogs of EP67 are also contemplated herein. “Conformationally-stable” means that the peptide is generally fixed in a single geometric orientation/conformation/molecular arrangement and not prone to conversion/rotation to a different orientation. In other words, rotation of bonds (particularly between the cis and trans configurations) is restricted or eliminated in the conformationally-stable analogs. Individual residue may also have a“constrained conformation,” which means that they do not undergo cisltrans isomerization. These conformationally-stable versions of the peptide adjuvant comprise, consist essentially, or consist of the formula:
Tyr-Ser-Phe-Lys-Asp-Met-Xaa-(Xaa2)-(D-Ala)-Arg (SEQ ID NO: l), or HC1 salt form thereof, wherein Xaa is a modified proline residue or a residue substitution for proline, and Xaa2 is leucine or N-methyl leucine. The modified proline residue, when used, is one
that lacks the cisltrans isomerization of unmodified proline. Advantageously, these peptides have a fixed conformation and selective C5a receptor binding activity. Such conformationally-stable analogs of EP67 are described in detail in co-pending WO 2016/0145365, filed March 11, 2016, and the details of such analogs are incorporated by reference herein in their entirety. Unlike the naturally flexible C5a structure, these peptide analogs are modified to be constrained in a rigid (specific) conformation, contributing to their specificity for C5aR-bearing APCs. Moreover, because cisltrans isomerization is avoided, the peptides are even more constrained in terms of their 3-dimensional binding structure than EP67.
According to one or more embodiments of the invention, exemplary peptide adjuvants include EP67 (where Xaa is P and Xaa2 is MeL, SEQ ID NO:2), EP144 (where Xaa is 2- aminoisobutyric acid and Xaa2 is L, SEQ ID NO:3), or EP145 (where Xaa is 5,5’-dimethylproline and Xaa2 is MeL, SEQ ID NO:4), which are depicted in Fig. 1. Other possible residue substitutions for the proline residue in EP7 are shown in Fig. 2, including 2-aminoadamantane-2- carboxylic acid, 2-azabicyclo[2. l . l]hexane-l-carboxylic acid, octahy dro- 1 //-i ndol e-2-carboxy 1 i c acid, 2-azaspiro[3.3]hepane-6-carboxylic acid, piperidine-4-carboxylic acid, and L- cyclohexylalanine (YSFKDM(Cha)LaR (SEQ ID NO: 1, where Xaa is cyclohexylalanine and Xaa2 is leucine). Further residue substitutions for the proline residue in EP67 are shown in Fig. 3, including pipecolic acid, 2-azetidinecarboxylic acid, among others shown.
In one or more embodiments, exemplary replacement residues for the proline residue of EP67 (Xaa) include alanine; leucine; isoleucine; N-methylalanine; 2-aminoisobutyric acid; 3- aminoisobutyric acid; N-methylisoleucine; singly-substituted proline analogs at the 2, 3, 4, and/or 5 positions of the pyrrolidine side chain; doubly-substituted proline analogs at the 2, 3, 4, and/or 5 positions of the pyrrolidine side chain; pseudoproline analogs: cysteine-derived thiazolidine, serine-derived oxazolidine, or threonine -derived oxazolidine; trifluoromethylated pseudoprolines; proline analog or homolog having a constrained conformation; trifluoromethylated azetidine 2- carboxylic acid; trifluoromethylated homoserine; oxetanyl-containing peptidomimetic; N- aminoimidazolidin-2-one analog; and nonchiral pipecolic acid analogs. Exemplary singly- or doubly-substituted substituted proline analogs include 5,5’-dimethylproline, 2,4-methano-P- proline, or 2,5-ethano-P-proline. Exemplary serine / threonine / cysteine-derived pseudoproline analogs are selected from the group consisting of:
group consisting of:
. Exemplary N-aminoimidazolidin-2- one analogs are selected from the group consisting of N-amino-imidazolidinone, a-amino-g- lactam, and an azapeptide.
Additional C-terminal analogs of C5a are also contemplated herein for use as the peptide adjuvant in the antiparasitic compound, including those comprising, consisting essentially, or consisting of the formula:
A 1 - Ser-Phe-Ly s- A2- A3 - A4- A5 - A6- A7 (SEQ ID NO:5) wherein: Al is Tyr, Trp, or N-acetyl derivatives of Tyr or Trp; A2 is Asp, Gly, Pro or N-methyl derivatives of Asp or Gly; A3 is Ala, Cys, Leu, Met or N-methyl derivatives of Ala, Cys, Leu or Met; A4 is Gln, Leu, Pro or N-methyl derivatives of Gln or Leu; A5 is Pro, Leu, a-methyl Leu or N-methyl Leu; A6 is D-Ala, Gly, D-Pro, aminoisobutyric acid (Aib) or N-methyl derivatives of D-Ala or Gly; and A7 is Arg or N-methyl Arg; such as peptides selected from the group consisting of:
Tyr-Ser-Phe-Lys-Pro-Met-Pro-Leu-(D-Ala)-Arg (SEQ ID NO:6);
Tyr-Ser-Phe-Lys-Asp-Ala-Pro-Leu-(D-Ala)-Arg (SEQ ID NO:7);
Tyr-Ser-Phe-Lys-Asp-Met-Pro-Leu-(D-Ala)-Arg (SEQ ID NO:8);
Tyr-Ser-Phe-Lys-Asp-Met-Pro-Leu-Gly-Arg (SEQ ID NO:9);
Tyr-Ser-Phe-Lys-Asp-Ala-Pro-Leu-Gly-Arg (SEQ ID NO: 10);
Tyr-Ser-Phe-Lys-Asp-Cys-Pro-Leu-Gly-Arg (SEQ ID NO: 11);
Tyr-Ser-Phe-Lys-Asp-Met-Pro-Leu-(D-Pro)-Arg (SEQ ID NO: 12);
Tyr-Ser-Phe-Lys-Asp-Met-Gln-Leu-(D-Ala)-Arg (SEQ ID NO: 13);
Tyr-Ser-Phe-Lys-Asp-Met-Gln-Leu-Gly-Arg (SEQ ID NO: 14);
Tyr-Ser-Phe-Lys-Asp-Met-Gln-Pro-Gly-Arg (SEQ ID NO: 15);
Tyr-Ser-Phe-Lys-Asp-Met-Pro-Leu-Aib-Arg (SEQ ID NO: 16);
Tyr-Ser-Phe-Lys-Gly-Met-Pro-Leu-Gly-Arg (SEQ ID NO: 17); and
Tyr-Ser-Phe-Lys-Gly-Leu-Leu-Leu-Gly-Arg (SEQ ID NO: 18).
In one or more embodiments, the anti-parasitic compound comprises (consists essentially or even consists of) the peptide antigen (or HC1 salt thereof) physically linked or conjugated to the peptide adjuvant, and more preferably conjugated to the amino-terminal end of the peptide adjuvant. In one or more embodiments, the peptide antigen is linked to the peptide adjuvant by a cleavable linker, such as a protease-sensitive dipeptide or oligopeptide. In one or more embodiments, the cleavable linker is sensitive to cleavage by a protease of the trypsin family of proteases. In one or more embodiments, the cleavable linker comprises a dibasic dipeptide sequence, such as an Arg-Arg dipeptide sequence or a tetrapeptide Arg-Val-Arg-Arg (SEQ ID NO:78), and the like. Various cleavable linkers can be synthesized by those skilled in the art. The components of the anti-parasitic compound can be made separately, then conjugated, or can be synthesized in tandem by peptide synthetic chemistry according to known methods.
Compositions comprising the anti-parasitic compound are also described herein. The compositions may comprise a single type of anti-parasitic compound (monovalent), or may include a cocktail or mixture of more than one anti-parasitic compound according to the embodiments of the invention (multivalent). For example, the composition could comprise two or more different peptide antigens, three or more different peptide antigens, four or more different peptide antigens, five or more different peptide antigens, even six or more different peptide antigens mixed together and administered as part of the same unit dosage form. In various embodiments, the composition comprises a pharmaceutically acceptable carrier. The term carrier is used herein to refer to diluents, excipients, vehicles, coatings and the like, in which the peptide(s) may be dispersed or coated with for administration. Suitable carriers will be pharmaceutically acceptable. As used herein, the term“pharmaceutically acceptable” means not biologically or otherwise undesirable, in that it can be administered to a subject without excessive toxicity, irritation, or allergic response, and does not cause unacceptable biological effects or interact in a deleterious manner with any of the other components of the composition in which it is contained. A pharmaceutically-acceptable carrier would naturally be selected to minimize any degradation of the compound or other agents and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art. Pharmaceutically-acceptable ingredients include those acceptable for veterinary use as well as human pharmaceutical use, and will depend on the route of administration. Any carrier compatible with the excipient(s) and the anti-parasitic compound can be used. Supplementary
active compounds may also be incorporated into the compositions.
A composition of the present disclosure is formulated to be compatible with its intended route of administration. Examples of routes of administration include oral administration (ingestion) and parenteral administration, e.g., intravenous, intradermal, subcutaneous, intraperitoneally, inhalation, nasal, transdermal (topical), transmucosal, buccal, sublingual, pulmonary and rectal administration.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water-soluble), solutions in sterile isotonic aqueous buffer, or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, Cremophor EL™ (BASF, Parsippany, N.J.), bacteriostatic/sterile water/distilled autoclaved water (DAW), or phosphate buffered saline (PBS). In all cases, the composition is sterile and fluid to allow syringability. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Fluidity is maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin. The injectable preparations may be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
Solutions or suspensions used for parenteral application (injection or infusion) may include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol, various oil-in-water or water-in-oil emulsions, as well as dimethyl sulfoxide (DMSO), or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH may be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
Oral compositions generally include an inert diluent or an edible carrier. Oral formulations
generally take the form of a pill, tablet, capsule (e.g., soft gel capsule, solid-filled capsule, or liquid-filled capsule), solid lozenge, liquid-filled lozenge, mouth and/or throat drops or spray, effervescent tablets, orally disintegrating tablet, suspension, emulsion, syrup, elixir, or tincture. The composition may be contained in enteric forms to survive the stomach or further coated or mixed to be released in a particular region of the gastrointestinal tract by known methods. Solid oral dosage forms are typically swallowed immediately, or slowly dissolved in the mouth. Oral compositions may also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Oral formulations optionally contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; starch or lactose; a disintegrating agent such as alginic acid, Primogel™, or com starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; and/or a sweetening agent such as sucrose or saccharin.
For administration by inhalation, the composition is optionally delivered in the form of a spray. The spray may be an aerosol spray from a pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. The composition is optionally formulated for delivery via a dry powder inhaler (DPI), a metered dose inhaler (pMDI), nasal spray, or a vaporizer. For routes of administration involving absorption of an agent and/or excipient through mucosal membrane, the composition further optionally comprises a penetrant.
Optionally, the composition is formulated as a“liquid respiratory composition,” i.e., a composition in a form that is deliverable to a mammal via the oral cavity, mouth, throat, nasal passage or combinations thereof. These compositions can be delivered by a delivery device selected from droppers, pump, sprayers, liquid dropper, spoon, cup, squeezable sachets, power shots, and other packaging and equipment, and combinations thereof. In one embodiment, the liquid respiratory composition comprises the therapeutic agent, and excipient, a thickening polymer (e.g., xanthan gum, cellulosic polymers such as carboxymethylcellulose (CMC), hydroxethylcellulose, hydroxymethylcellulose, and hydroxypropylmethylcellulose, carrageenan, polyacrylic acid, cross-linked polyacrylic acid such as Carbopol®, polycarbophil, alginate, clay, and combinations thereof), and optionally a mucoadhesive polymer (e.g., polyvinylpyrrolidone (Povidone), methyl vinyl ether copolymer of maleic anhydride (Gantrez®), guar gum, gum tragacanth, polydextrose, cationic polymers, polyethylene oxide), poly(ethylene glycol), poly(vinyl alcohol), poly(acrylic acid), cross-linked polyacrylic acid such as Carbopol®, polycarbophil, poly(hydroxyl ethyl methacrylate), chitosan, cellulosic polymers such as
carboxymethycellulose (CMC), hydroxethylcellulose, hydroxymethylcellulose, and hydroxypropylmethylcellulose, and combinations thereof). The composition is preferably a non- Newtonian liquid that exhibits zero shear viscosity from about 100 centiPoise (cP) to about 1,000,000 cP, from about 100 cP to about 500,000 cP, from about 100 cP to about 100,000 cP, from about 100 cP to about 50,000 cP, from about 200 cP to about 20,000 cP, from about 1,000 to about 10,000 cP at a temperature of about 37 °C, as measured according to the Shear Viscosity Method. The pH range of the formulation is generally from about 1 to about 7, from about 2 to about 6.5, and from about 4 to about 6.
In general, additional pharmaceutically-acceptable ingredients for use in the compositions include buffering agents, salts, stabilizing agents, diluents, preservatives, antibiotics, isotonic agents, cell media (e.g., MEM, FBS), flavoring agents, and the like. Exemplary isotonic agents include dextrose, lactose, sugar alcohols (e.g., sorbitol, mannitol), and the like. Stabilizing agents include sugars such as sucrose and lactose, amino acids such as glycine or the monosodium salt of glutamic acid and proteins such as albumin or gelatin, and mixtures thereof. Exemplary preservatives include formaldehyde, thimerosal, and the like.
In various embodiments, in addition to the carrier and peptide analogs described herein, a nasal spray formulation may comprise benzalkonium chloride, camphor, chlorhexidine gluconate, citric acid, disodium EDTA, eucalyptol, menthol, purified water, and/or tyloxapol. An exemplary oral composition may comprise FD&C Blue No. 1, gelatin, glycerin, polyethylene glycol, povidone, propylene glycol, purified water, sorbitol special, and/or titanium dioxide in addition to an excipient and acetaminophen, doxylamine succinate, and phenylephrine HC1 (or dextromethorphan) .
The formulation is provided, in various aspects, in unit dosage form for ease of administration and uniformity of dosage. “Unit dosage form” as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated, each unit containing a predetermined quantity of the anti-parasitic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms are dictated by and are directly dependent on the unique characteristics of the excipient(s) and therapeutic agent(s) and the particular biological effect to be achieved.
Safety and efficacy of compositions described herein are determined by standard procedures using in vitro or in vivo technologies, such as the materials and methods described herein and/or known in the art. Administration may be on an as-needed or as-desired basis, for example, once-monthly, once-weekly, or daily, including multiple times daily, for example, at
least once daily, from one to about ten times daily, from about two to about four times daily, or about three times daily. A dose of composition optionally comprises about from about 0.001 mg to about 1000 mg active agent, alternatively from about 2.5 mg to about 750 mg active agent, and alternatively from about 5 mg to about 650 mg of the active agent. In one embodiment, a dose of composition according to the present disclosure comprises about from 0.1 mg to about 0.25 mg. In various embodiments, a dose of composition according to the present disclosure comprises 25 pg, 50 pg, 60 pg, 70 pg, 80 pg, 90 pg, 100 pg, 125 pg, 150 pg, 175 pg, 200 pg, 225 pg, 250 pg, 275 pg, 300 pg, 325 pg, 350 pg, 375 pg, 400 pg, 425 pg, 450 pg, 475 pg or 500 pg. In various embodiments, a dose of composition according to the present disclosure comprises between 25 pg to 500 pg, 50 pg to 400 pg, 100 pg to 300 pg, or 200 pg to 250 pg.
The anti-parasitic compounds and associated compositions are used to induce innate and acquired immune responses against parasites while sparing inflammation. The anti-parasitic compound binds specifically to the C5a receptor on the antigen presenting cell. This binding is followed by internalization of the peptide antigen, which is cleaved from the peptide adjuvant once internalized in the cell, and results in presentation of the antigen moiety on the surface of the antigen presenting cell. In one or more embodiments, compositions used according to the invention comprise a plurality of anti-parasitic compounds, and specifically different anti-parasitic compounds, each comprising a different peptide antigen. Such“cocktail” compositions can be useful to deliver multiple different peptide antigens each conjugated to a peptide adjuvant, and initiate a more robust immune response. The same peptide adjuvant can be used in the composition across the different types of peptide antigens. Alternatively, different peptide adjuvants can be used for different types of peptide antigens. The compositions may be formulated with different antigens to target different types of parasites (i.e., broad spectrum or“cocktail”). Alternatively, the composition may be formulated with different antigens that are nonetheless specific to one particular target parasite.
In one or more embodiments, the target parasite is a protozoan, and particularly a pathogenic protozoan that causes infection in humans or animals. Exemplary target parasites are protozoans, including, without limitation, Entamoeba histolytica, Eimeria spp. ( bovi , brunetti, maxima, mitis, acervuline, meleagrimits, crandallis, ovinoidalis, bakuensis, arloingi, ninakohlyakimovue, debliecki, leuckarti, intestinalis, zuernii, auburnesis, alabamensis, phocae, weddelli, alpacae, invitaensis, lamae, macusaniensis, punonensis, couesii, kinsellai, palustris, ojastii, oryzomy i, necatrix, tenella, stiedae , etc.), Isospra spp., Besnoitia spp. ( besnoiti , caprae , etc.), Babesia spp. {bovis, bigemina, berbera, caballi, equi, perroncitoi, tralirmanni, argentina,
diver gens, microti, major, jakimovi, ovata, molasi, ovis, etc.), Balantidium coli , Giardia spp. {lamblia/duodenalis, intestinalis , etc.), Neospora caninum , Trichomonas vaginalis , Trypanosoma spp. ( brucei , cruzi, vivax, theileri, congolense, simiae, melophagium, uniforms, equiperdum , etc.), Theileria spp. (parva, annulata, orientalis, velifera, taurotragi, sergenti, lestoquardi, mutans, hirci, ovis , etc.), Leishmania spp. {major, tropica, aethiopica, mexicana, amazonensis, venezuelensis, braziliensis, guyanensis, panamensis, peruviana, donovani, infantum/ chagasi, etc.), Toxoplasma gondii, Plasmodium spp. {vivax, falciparum, ovale , etc.), Sarcocystis spp. {cruzi, hirsuta, hominis, tenella, gigantica, capracanis, hircicanis, moulei , etc.), Spironucleus , Histomonas meleagridis, Cryptosporidium spp. {parvum, andersoni, felis, etc.), Cytauxzoon felis , Cystoisospora belli , Tritrichomonas spp. {foetus , blagburni , augusta, etc.), Pentatrichomonas hominis , and the like.
In use, a therapeutically-effective amount of the anti-parasitic compound is administered to a subject in need thereof. Administration of the anti-parasitic compound elicits an immune response in the subject, and more specifically a selective activation of the innate immune response, without direct activation of pro-inflammatory neutrophils and other granulocytes. The immune response will be demonstrated by a lack of observable clinical symptoms, or reduction of clinical symptoms normally displayed by an infected subject, faster recovery times from infection, reduced duration of infection, and the like. In another embodiment, a method of activating an immune cell at a site of infection or disease is provided comprising administering an effective amount of the anti-parasitic compound to a mammal, wherein the anti-parasitic compound has selective C5a receptor binding activity for targeted delivery and uptake of the peptide antigen. It will be appreciated that although the anti-parasitic compound does not directly bind or activate the pro- inflammatory granulocytes, a secondary inflammatory response may be initiated due to the release of chemokines/cytokines by the APCs once activated by the anti-parasitic compound.
A kit comprising the anti-parasitic compound is also disclosed herein. The kit further comprises instructions for administering the anti-parasitic compound to a subject. The anti- parasitic compound can be provided as part of a dosage unit, already dispersed in a pharmaceutically-acceptable carrier, or it can be provided separately from the carrier. The kit can further comprise instructions for preparing the anti-parasitic compound for administration to a subject, including for example, instructions for dispersing the anti-parasitic compound in a suitable carrier.
It will be appreciated that therapeutic and prophylactic methods described herein are applicable to humans as well as any suitable warm-blooded animal, including, without limitation,
dogs, cats, and other companion animals, as well as, rodents, primates, horses, cattle, sheep, pigs, etc. The methods can be also applied for clinical research and/or study.
As used in the present disclosure, the term “treating” or “treatment” refers to an intervention performed with the intention of preventing the development or altering the pathology of infection. Accordingly,“treatment” refers to both therapeutic treatment and prophylactic or preventative measures. A therapeutic agent may directly decrease the pathology of infection, or render the infection more susceptible to treatment by other therapeutic agents or, for example, the host’s immune system. Improvement after treatment may be manifested as a decrease or elimination of such symptoms. Thus, the compositions are useful in treating a the infection by preventing the development of observable clinical symptoms from infection, and/or reducing the incidence or severity of clinical symptoms and/or effects of the infection, and/or reducing the duration of the infection/symptoms/effects.
As used herein, the phrase“effective amount” or“therapeutically effective amount” is meant to refer to a therapeutic or prophylactic amount of the anti-parasitic compound or its antigenic peptide that would be appropriate for an embodiment of the present disclosure, that will elicit the desired therapeutic or prophylactic effect or response, including alleviating some or all of such symptoms of infection or reducing the predisposition to the infection, when administered in accordance with the desired treatment regimen. One of skill in the art recognizes that an amount may be considered therapeutically“effective” even if the condition is not totally eradicated or prevented, but it or its symptoms and/or effects are improved or alleviated partially in the subject. The therapeutically effective dosage of anti-parasitic compound or its antigenic peptide may vary depending on the size and species of the subject, and according to the mode of administration.
Additional advantages of the various embodiments of the invention will be apparent to those skilled in the art upon review of the disclosure herein and the working examples below. It will be appreciated that the various embodiments described herein are not necessarily mutually exclusive unless otherwise indicated herein. For example, a feature described or depicted in one embodiment may also be included in other embodiments, but is not necessarily included. Thus, the present invention encompasses a variety of combinations and/or integrations of the specific embodiments described herein.
As used herein, the phrase "and/or," when used in a list of two or more items, means that any one of the listed items can be employed by itself or any combination of two or more of the listed items can be employed. For example, if a composition is described as containing or excluding components A, B, and/or C, the composition can contain or exclude A alone; B alone;
C alone; A and B in combination; A and C in combination; B and C in combination; or A, B, and C in combination.
The present description also uses numerical ranges to quantify certain parameters relating to various embodiments of the invention. It should be understood that when numerical ranges are provided, such ranges are to be construed as providing literal support for claim limitations that only recite the lower value of the range as well as claim limitations that only recite the upper value of the range. For example, a disclosed numerical range of about 10 to about 100 provides literal support for a claim reciting "greater than about 10" (with no upper bounds) and a claim reciting "less than about 100" (with no lower bounds).
EXAMPLES
The following examples set forth methods in accordance with the invention. It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.
EXAMPLE 1
Peptide Antigen Selection
Selection of peptides for inclusion in Toxoplasma gondii peptide-based EP67 vaccines. Criteria for selecting antigenic peptides to include in the vaccine with the C5aR agonist peptide (e.g., EP67) include:
-Amino acid sequence distinct by at least 2 amino acids from human, mouse, cow, pig, sheep, dog, and cat
-Demonstrated immunogenic MHC class I epitope in humans and/or mice
-Demonstrated immunogenic MHC class II epitope in humans and/or mice
-Demonstrated immunogenic capacity to promote IgM and IgG B cell responses
-Peptide/epitope between 9-15 amino acids in length
-(Section of) protein shown to possess chronic or acute protective effects in mice vaccine attempts
-(Section of) protein shown to elicit T cell efficacy in humans and/or mice
-(Section of) protein shown to elicit serum responses in humans and/or mice
-Epitope is derived from a parasite protein expressed in tachyzoite and bradyzoite stage -Computer predicted immunogenicity of MHC class I epitope in B ALB/c haplotype -Epitope is derived from a parasite protein expressed at the top 2/3rds of abundant
transcripts
-Epitope is derived from a parasite protein expressed on the surface or during invasion
EXAMPLE 2
Peptide Chemistry
Peptides were synthesized with the following antigenic sequences for Toxoplasma gondii , and conjugated to either EP67 or a scrambled EP67 sequence (as a control).
25 mg of each of the following full length anti-parasitic compounds were synthesized in the HC1 salt form. All amino acids are L-form except the single“a” residue in each peptide, which is D- form. Residue“MeL” designates an N-methyl leucine.
Additional predicted HLA peptides include: VVFVVFMGV (GRA6; SEQ ID NO:37); FMGVLVNSL (GRA6; SEQ ID NO: 38); FLVPFVVFL (GRA3; SEQ ID NO: 39); KSFKDILPK (SAG1; SEQ ID NO:40); AMLTAFFLR (GRA6; SEQ ID NO:4l); RSFKDLLKK (GRA7; SEQ ID NO:42); LPQFATAAT (GRA7; SEQ ID NO:43); VPFVVFLVA (GRA3; SEQ ID NO:44); HPGSVNEFDF (GRA6; SEQ ID NO:45); STFWPCLLR (SAG2C 13-21; SEQ ID NO:46); AVVSLLRLLK (SPA/GRA5 89-98; SEQ ID NO:47); and SSAYVFSVK (SRS52A 250-258; SEQ ID NO:48). Other HLA-A*0201 candidates include:
It will be appreciated that new sequences may need to be derived or codon optimized for each target species of patient to be treated (generally homologous sequences to those described above). It will be generally appreciated that appropriate sequences will be continually sought through the interrogation of the parasite sequences with species specific MHC epitope-identifying tools using different algorithms, as guided by the selection criteria described herein. See also, Tan et al., Identification of I gondii epitopes, adjuvants, & host genetic factors that influence protection of mice & humans , Vaccine. 2010 May 21; 28(23): 3977-3989; Cong et al., Towards an immunosense vaccine to prevent toxoplasmosis: Protective Toxoplasma gondii epitopes restricted by HLAA *020f Vaccine. 2011 January 17; 29(4): 754-762; Cong et al., Human immunome, bioinformatic analyses using HLA supermotifs..., Immunome Research 2010, 6: 12 (open access); and Cong et al., Toxoplasma gondii HLA-B* 0702 restricted GRA720 28 peptide with adjuvants..., Hum Immunol. 2012 January, 73(1): 1-10, each of which is incorporated by reference herein with respect to disclosed epitope sequences.
EXAMPLE 3
Peptide Synthesis
Six T gondii vaccines were synthesized: Vaccine 1 : SAGI242-256 (SEQ ID NO: 25); Vaccine 2: GRAlm-ise (SEQ ID NO: 26); Vaccine 3: AMAHi-ss (SEQ ID NO: 27); Vaccine 4: SAG3208-222 (SEQ ID NO: 28); Vaccine 5: GRA6210-224 (SEQ ID NO: 29); Vaccine 6: GRA7I4-28 (SEQ ID NO: 30). The peptides were an unexpected synthetic challenge, but were ultimately synthesized for testing. Vaccines were purified with analytical and preparative HPLC and characterized with electrospray mass spectrometry:
Vaccine 1 : Mcaic = 3334, (M + 2H)2+ = 1673, (M = 3H)3+ = 1113;
Vaccine 2: Mcaic = 3376; (M + 2H)2+ = 1689; (M + 3H)3+ = 1126; (M = 4H + = 848 Vaccine 3: Mcaic = 3131; (M + 2H)2+ = 1566, (M + 3H)3+= 1045;
Vaccine 4: Mcaic = 3155, (M + 2H)2+ = 1578, (M + 3H)3+ = 1052, (M + 4H)4+ = 789 Vaccine 5: Mcaic = 3320; (M = 2H)2+ = 1661; (M + 3H)3+ = 1107; (M + 4H)4+ = 831 Vaccine 6: MWcaic = 2938; (M + 2H)2+ = 1469.6; (M + 3H)3+ = 980.4
The doubly- and triply-charged fragmentation ions were consistent with and corresponded to the calculated molecular weights.
Inactive vaccines were also constructed, either with scrambled EP67 or the reverse orientation constructs (with EP67 at the N-terminal end, e.g., EP67-RR-epitope), as negative controls using“inactive” constructs that have the same amino acid composition as the“active” EP67-based vaccines. Synthesis, purification, and characterization was carried out of the T. gondii epitopes and the biologically inert vaccines; i.e., the reverse orientation constructs (EP67 on the N-terminal side and the epitope on the C-terminal side) and the normal orientation constructs, but with scrambled sequence EP67 on the C-terminal side.
Free EP67 (unattached to any epitope) was used as a control to stimulate murine bone marrow-derived dendritic cells (See Table 1 below). Preliminary data show that EP67 is capable of inducing all four cytokines initially evaluated: IL-10, CXCL1, TNF-alpha, and IL-6. Testing these and additional cytokines (at the gene and protein-expression levels) against all of the synthesized and control vaccines is carried out. Similarly, we will also be analyzing surface marker expression indicative of DC activation.
Table 1: qPCR Detection of Cytokine Expression Following Exposure to EP67
EP67 (50 pg/ml) was incubated with bone marrow-derived mouse dendritic cells (24 hrs) following in vitro maturation. Fold changes in expression were compared to PBS controls and normalized to Actin B gene expression. Three replicates were analyzed per gene. The results show that EP67, compared to PBS controls, caused increased expression of IL-10, CXCL1, TNF- alpha and IL-6. A positive control, bacterial LPS, was also evaluated and produced upregulation of at least 20-fold above PBS controls for all evaluated cytokines.
EXAMPLE 4
Cytokine Release Caused by EP67 Analogs
The synthesis of these vaccines has been an unexpected synthetic challenge. While all vaccines have been synthesized using our standard solid-phase methods, HPLC purification has been challenging given the inefficiency of individual coupling reactions, particularly as the peptide increases in length. Against this backdrop, considerable time was spent in implementing an improved method of synthesis to overcome this problem, using a variety of coupling reagents.
Purification/Desalting. An improved method for generating the HC1 salt forms of the peptides was developed. Our standard method of HPLC purification used 0.1% TFA as the running buffer and peptides were brought off the Cl 8 column with a gradient of 60% acetonitrile in 0.1% TFA. This method is used by numerous laboratories and has served us well for many years. However, the final peptide is in the trifluoro-acetate salt form, which some have reported to be disruptive in biological systems due to the generation of TFA. Thus, we have interests in generating the FDA-acceptable HC1 salt forms of these T. gondii vaccines.
In one approach, the HC1 salt forms of our peptides were generated by mixing the peptide in a water slurry with the strong anion exchange resin Amberlite IRA-400 Cl for a few hours. While this was effective in removing most of the TFA counter anions, it was not 100% effective (as indicated by 19F-NMR). Also, the anion exchange resin gave a slight color change to the otherwise white peptide along with a fair amount of micro resin particles that required filtration. Once removed, the peptide in aqueous solution needed to be re-lyophilized to the dry powder. This desalting, filtering, and lyophilizing process was time consuming and added the possibilities of introducing impurities to the final product.
Another approach is an improved single-step method for generating the HC1 salt forms of the above vaccines. This was accomplished by first eliminating the use of TFA in our HPLC purification. In place of 0.1% TFA we used 2% trimethylamine/phosphoric acid buffer, which we found to be an excellent buffer system particularly at the high flow rates we use on our preparative column for final purification of the crude peptide. Under these conditions, the phosphate salt of the peptide is generated, but it is easily exchanged with the HC1 salt by loading the peptide onto the same preparative column equilibrated with 5mM HC1 and bringing it off with a rapid gradient of acetonitrile. This method of purification and desalting is now our standard operating procedure for all peptides generated in our laboratory.
Cytokine Analysis. Considerable time was spent in learning the methods for the rapid, efficient, and high throughput method of cytokine analysis using a multiplex instrument for large
panels of cytokines (MesoScale QuickPlex SQ 120). With this instrument, we tested the EP67- and analogue-mediated release of a pro-inflammatory and anti-inflammatory panel of cytokines (IL-lbeta, IL-2, IL-4, IL-6, IL-10, IL-l2p70, IL-13, IL-15, TNF-a, and IFN-gamma) from human monocytes and monocyte-derived dendritic cells over the course of 6 and 24 hours of exposure 50 pg/ml EP67, scrambled EP67 (scEP67), and EP67 analogues (EP144, EP146, and EP147). These results are shown in Fig. 4. It was encouraging to see cytokine release from EP67-treated cells and interesting to note an increase in cytokine release from the analogue EP147 (cha substitution for proline).
EXAMPLE 5
Improved Synthesis of Peptides
The analytical HPLC chromatograms of each epitope and EP67-based vaccine were analyzed. In all cases, HPLCs were run on Cis-bonded silica reverse-phase columns equilibrated with 0.5% trimethylamine (v/v) and 0.5% phosphoric acid (v/v) (TEAP buffer pH 2.3 - solvent system A) and peptides eluted with an increasing gradient of 60% acetonitrile in TEAP (solvent system B). Analytical flow rates were 1.5 mL/min and preparative flow rates were 60 mL/min. In both analytical and preparative modes, peptide separations were monitored at 214 nm.
Synthesis of the epitopes was carried out and the crude chromatograms indicated a reasonably clean mixture after resin cleavage and peptide precipitation. Each epitope was purified using preparative HPLC in the manner described above and was generated in the HC1 salt form using newly developed methods.
Synthesis of the EP67-based vaccines was more challenging, but our improved synthetic methods gave a significant improvement in yield and purity as indicated by the crude analytical chromatograms after resin cleavage and peptide precipitation. Each EP67-based vaccine was purified using preparative HPLC as described above and generated in the HC1 salt form. The exception was vaccine #5 (GRA6210-224), which gave two prominent analytical peaks, both of which were collected and analyzed by mass spectrometry. Neither peak, however, gave the calculated molecular weight. The larger of the two peaks generated a molecular weight suggestive of an extra Ser reside during synthesis.
Finally, we began the synthesis of the negative-control“inactive” vaccines; i.e., the same constructs in the above table, but with scrambled sequence EP67 in place of normal sequence EP67. “Inactive” vaccines #1 and #2 have been synthesized.
The crude analytical HPLC chromatograms of each“inactive” vaccine construct were analyzed. As before, HPLCs were run on Cis-bonded silica reverse-phase columns equilibrated with 0.5% trimethylamine (v/v) and 0.5% phosphoric acid (v/v) (TEAP buffer pH 2.3 - solvent system A) and peptides eluted with an increasing gradient of 60% acetonitrile in TEAP (solvent system B). The HC1 salt forms of these peptides were generated by loading the peptide collected from the TEAP preparative run onto the same preparative column, but equilibrated with 5 mM HC1 and brought off the column with a gradient of acetonitrile (0 - 50%) of acetonitrile over 5 minutes. Analytical flow rates were 1.5 mL/min and preparative flow rates were 60 mL/min. In both analytical and preparative modes, peptide separations were monitored at 214 nm.
EXAMPLE 6
Generation and Activation of Human DCs
We established the ability to routinely generate human DCs. Fig. 5 shows the immunophenotypes of human dendritic cells generated from peripheral blood monocytes as analyzed with flow cytometry. Human peripheral blood monocytes (obtained from the elutriation core facility at the University of Nebraska Medical Center) were incubated in the presence of IL- 4 (400 U/ml) and GM-CSF (800 U/ml) for 6 days with half of the media replaced at day three. The resulting cells expressed high levels of surface markers CD80, CD83, CD86, HLA-ABC, HLA-DR characteristic of DCs.
EP67 Differentiates Human Peripheral Blood Monocytes to Cells with Phenotypes Characteristic of Macrophages/DCs. EP67, but not scrambled EP67, converts rounded and non- adhered monocytes into elongated, adhered cells that display spindle-like features characteristic of macrophages/DCs. Fig. 6 shows human monocytes (ca. 104) incubated 48 hrs in the presence of 50 pg/ml of scrambled sequence EP67 (Panel A) and EP67 (Panel B).
EP67 Differentiates Human Peripheral Blood Monocytes to Cells with Immunophenotypes Characteristic of Macrophages/DCs. Human monocytes were incubated with EP67 (50 pg/ml) and surface markers analyzed over the course of 7 days. The data shows that EP67 moderately enhanced the expression of CD14, CD16, CDl lb, and CD33, but significanlty enhanced the expression of CD80 and CD206, which are characteristic of macrophages and DCs.
EP67 Induces Cytokine Release from Human Macrophages and DCs (Fig. 7). Human monocyte-derived macrophages and DCs were incubated with EP67 (50 pg/ml) and scrambled EP67 (50 pg/ml) for 6 and 24 hours. Supernatants were collected and analyzed for the presence of the following cytokines: IL-lbeta, IL-2, IL-4, IL-6, IL-10, IL-l2p70, IL-13, IL-15, TNF-alpha,
and IFN-gamma. Fig. 7 shows graphs of Cytokine release from human DCs and macrophages (MC) incubated for 6 and 24 hours with EP67 (50 pg/ml), scrambled (sc) EP67 (50 pg/ml), and media only (Me). As shown in Fig. 7, EP67 (but not scrambled EP67) induced the release of predominately IL-lbeta, IL-2, IL-6, IFN-gamma, and TNF-alpha after 24 hours of incubation with macrophages and DCs. Interestingly, the levels of cytokines induced and the distinction of cytokine release between EP67 and controls was more pronounced in macrophages than in DCs. It is worth noting that the prominent cytokines relased at 6 and 24 hours in response to EP67 (IL- lbeta, IL-2, IL-6, and TNF-alpha) represent a THl/pro-inflammatory bias relative to the TH2/anti- inflammatory cytokines (IL-4, IL-5, IL-10, and IL-13). This THI bias is in keeping with earlier observations with EP67 and is an important immunologic component for an effective immune response to T. gondii.
EP67 Induces Cytokine Release from Murine Splenocytes (Fig. 8). Splencocytes were obtained from normal Balb/c mice (ca. 2 months) and aged (ca. 17 months) sentinel mice of undetermined backgroud (a gift from the University of Nebraska Medical Center Animal Facility). Spelocytes were cultured in the presence of EP67 and scrambled EP67 (50 pg/ml) for 24 hours, supernatants harvested, and analyzed for the presence of IL-lbeta, IL-2, IL-4, IL-5, IL-6, KC/GRO, IL-10, IL-l2p70, TNF-alpha, and IFN-gamma. Fig. 8 shows Cytokine release from Balb/c splencoytes (left panel) and splenocytes obtained from aged sentinel mice (right panel) incubated with EP67 and scrambled EP67 (50 pg/ml) for 48 hours. As shown in Fig. 8, there was little effect of EP67 in cytokine release relative to controls in the Balb/c splenocytes. A more pronouned effect, however, was observed with the aged sentile mice. Splenocytes were not our original choice of APCs from mice to evaluate the effects of EP67/EP67-based vaccines, but they were chosen for this first assessment as a matter of convenience to help with getting our cell culture protocols and assays established and verified.
Summary. We have established the ability to generate human macrophages and DCs and verified their ability to respond to EP67 by upregulation of surface activation markers and cytokine release. These cells will be used for the analogous in vitro assessment of activity of the EP67- based vaccines to T. gondii already generated and chemically verified. We also generated murine APCs in form of splenocytes. As mentioned above, these were used as an initial and convenient way to optimize our cell culture conditions and our multiplex cytokine release assays. Our objective moving forward is to establish the ability to generate more“purified” murine APCs (macrophages and DCs) in a manner consistent with what we showed this month with human macrophages/DCs.
EXAMPLE 7
Activation of Murine DCs by EP67 Vaccines
A subset of vaccines were developed with murine DC’s from BALB/c bone marrow, and examined for cytokine response. Fig. 9 shows murine dendritic cell activation following 6hr exposure to EP67 vaccines. Bone marrow-derived BALB/c DCs were separately exposed to EP67- containing vaccines #1 (TgSAGl) and #2 (TgGRAl) (Example 3), and compared to sham exposure (media). The results were promising for the two vaccines that we tested (Fig. 9) in that exposure led to cytokine release above the controls, but only KC/GRO achieved at least an 80% increase compared to sham (our criteria for active vaccines). KC/GRO, also known as CXCL1, is a potent neutrophil chemotactic cytokine. Increases in INF-gamma, IL-lb, and TNF-a were also observed, and are in-line with expectations of EP67 engagement of the C5a receptor and subsequent activation of dendritic cells.
EXAMPLE 8
Expression of Leukocyte Surface Markers Indicative of Activation EP76-containing vaccines were investigated and found to increase surface activation markers of exposed white blood cells, such as DCs shown in Fig. 10, which were exposed for 6 hours to Vaccines #1 (TgSAGl) and #2 (TgGRAl). Following exposure, cells were fixed and stained with antibodies to measure cell surface markers of intact cells by flow cytometry. Increases were observed in key markers of activation, including a sizeable increase (passing the required threshold of 80% increase) in CD80 from EP67 vaccine #2. Elevation occurred in CD80, CCR7, and MHC Class II molecules, indicating activation of dendritic cells compared to control (media only). As noted previously, human in vitro experiments suggest that EP67 containing vaccines more strongly activate macrophages following a six hour exposure.
EXAMPLE 9
EP67 Vaccines Exhibit No Measurable Toxicity
Weight loss in mice is common signal of toxicity when exposed to foreign substances. EP67-containing vaccines would be ideal if no toxicity were observed during treatment. As seen in Fig. 11, no significant weight loss occurred following treatment of the mice (treated as outlined in Fig. 14). Fig. 11 shows recorded weights indicating a lack of toxicity in EP67-vaccinated mice. Mice administered all EP67-containing vaccines (“Hexavalent IP”) at a total of 20ug showed steady increases in weight, along with scrambled vaccine and PBS controls, in addition to EP67
mixed with parasite lysate. This is indicative of a lack of overt toxicity by EP67-containing vaccines in treated mice.
Another criteria to be met which demonstrates antigen-specific immune activation is the splenic lymphoproliferative assay. Fig. 12 demonstrates that mice were specifically reactive to antigens when previously vaccinated with EP67-containing vaccines. Fig. 12 shows results from the lymphoproliferative assay indicating specific antigen response. Groups of mice (n=3) were vaccinated according to the scheme in Fig. 14. At day 45, mice were sacrificed and spleens removed. Following isolation, splenocytes were exposed for 72 hours to individual antigens (lacking EP67 moiety), then to MTT for 4 hours and quenched with DMSO. Absorbance was read at 540nm, and relative increases in absorbance from unstimulated splenocytes were plotted. In ALL cases, antigens caused splenocytes proliferation in vaccinated mice, and not in PBS-treated mice. All p values <0.01 except SAG1, which is p=0.0l 1 when evaluated by the Student’s t test.
EXAMPLE 10
EP67 Vaccines Activate Murine Macrophages
Although murine work was achieved using commercially available BALB/c cells, we felt it useful to explore additional cell options for in vitro evaluation of EP67 vaccine candidates. Using RAW 264.7 transformed cell lines, we were able to repeat the findings that EP67 does indeed activate this murine macrophage cell line, as measured by expression of TNF-alpha and IL- 6 at levels significantly higher than media controls. Figs. 13 A and 13B show the results of RAW 264.7 cells activated by EP67. In order to evaluate a cell line that is responsive to both EP67 and C5a (the complement protein from which the sequence of EP67 is derived), RAW 264.7 were tested for secretion of TNF-a and IL-6. For both cytokines, supernatants from both 6hr and 24hr exposures of recombinant C5a were high. Additionally, EP67 caused statistically significant (p<0.05) increases in these two cytokines, with more pronounced effects at the later (24hr) timepoint.
EXAMPLE 11
EP67 Vaccine Confers Specific Immunity as Measured by IFN-gamma release
Following the vaccination scheme outlined in Fig. 14, murine splenocytes were isolated from vaccinated and sham -vaccinated (control) mice. Fig. 15 demonstrates that the potent Thl- inducing interferon-gamma cytokine is released at significantly greater levels (p<0.0l) when exposed to vaccinated antigen peptide vs splenocytes from control-treated mice. This indicates
that EP67 vaccines can generate a specific, robust immune response against foreign peptides when vaccinated in this manner.
EXAMPLE 12
Vaccination with EP67 Vaccines Prevented Mouse Death Following Acute Infection Mice were infected with 5,000 ME49 T. gondii parasites intraperitoneally following 3 rounds of vaccine treatment. Non-vaccinated (PBS) mice (n=20) experienced incomplete lethality. A Student’s t test of difference between PBS and Hexavalent EP67 vaccine intraperitoneal administration yielded a p-value of 0.08, indicating a strong likelihood of protection from EP67- containing vaccines. (Fig. 17) The recombinant parasite protein SAG1 co-administered with EP67 did not elicit any immune protection. As a positive control, ME49 parasite lysate was administered in conjunction with Thl -stimulating CpG DNA. Fig. 18 demonstrates an adaptive immune response in the vaccinated mice.
EXAMPLE 13
Vaccine Prevented Parasite Encystment in Humanized Mice Humanized mice (containing a human MHC locus) received 4 vaccine administrations, or PBS as a No Vaccine control, and challenged 15 days with T. gondii following the final vaccination. 21 days post-infection, surviving mice were sacrificed and brains removed to ascertain brain parasite cyst loads via qPCR detection. Parasite cyst loads, relative to brain DNA in each sample, was calculated and showed at least a 28-fold decrease in cysts, with the potential for no cysts in the brain. A Students t test showed a p value of 0.01 between vaccinated and unvaccinated animals (Fig. 19). This data indicates that EP67 vaccines were able to substantially reduce brain tissue cysts in the brains of vaccinated and infected mice which contain elements of human adaptive immunity compared to sham-treated mice.
Conclusions
The anti-parasitic vaccines can generate specific splenic immune responses against l5mer antigens. The anti-parasitic vaccines can protect vaccinated mice against acute T. gondii infection w / p-value=0.08. The anti-parasitic vaccines significantly reduce brain cysts w / p-value<0.0l .
EXAMPLE 14
Treatment of pigs for T. gondii
The efficacy of the vaccines in generating an adaptive immune response as well as providing protection from chronic infection in pigs is investigated. Vaccines are prepared as described above. Vaccine sequences may be sequence optimized for pigs and synthesized accordingly. Pigs are first screened and identified as potential carriers of the parasite. Pig sera was received. ELISA plates coated with T. gondii soluble lysate were rinsed and soaked overnight with provided sera. After rinsing, goat anti-pig IgG labeled antibodies were added followed by a final rinse and HRP activation and absorbance reading. The sera were run in two separate replicate experiments, with identical results. Mouse positive and negative controls were used. Generally (in mice serology) an absorbance reading below 0.5 is considered negative. Between 0.5 and 1 is considered potentially positive. And above 1.0 is considered positive. As shown in Fig. 20, several of the pig sera contained IgG antibodies against T. gondii , although #32 and #34 would be considered negative.
Five separate groups of these pigs (10 pigs per group) will be immunized with:
1) Individual vaccines modeled on the ones identified in this application for mice but optimized for pigs using PigMatrix or other available swine MHC prediction tools
2) Pooled vaccines (2 or more vaccine combinations);
3) EP67-inactivated vaccines (scrambled or reversed orientation);
4) T. gondii epitopes only; and
5) Phosphate buffered saline (PBS) only.
Pigs screened and identified to have a high parasite burden (Fig. 20) will receive a total of up to 10 mg vaccine/peptide per dose in 3 doses every 15 days (e.g., days 0, 15, and 30). Each pig will be weighed and observed daily to identify any apparent toxicity. Two pigs from each group will be sacrificed and the spleen harvested to evaluate lymphoproliferative properties when mesh- purified and separately splenocytes are exposed to 50 pg/mL total parasite lysate (positively controlled by concanavalin A). Cell-free supernatants from this exposure will be probed via ELISA for secretion of IFN-gamma, considered vital in preventing Toxoplasma-induced acute disease following infection. ETsing collected sera, Western blots against total parasite lysate (or alternatively, purified recombinant protein) will confirm the target protein of the humoral response, and ELISA will quantitatively evaluate humoral response. The remaining pigs in each group will then be used for protection experiments (below).
It is anticipated that the pooled vaccine combination will produce the most significant TH1
adaptive immune responses as evidenced by these proposed experiments. As Toxoplasma relies primarily on its ability to rapidly disseminate in the host prior to adaptive immune activation, it is hypothesized that this EP67-adjuvanted approach using epitopes of T. gondii will be sufficient to prevent the deleterious effects of infection.
On Day 45, from the remaining pigs in each group, half will receive a sub-lethal dose of T. gondii strain ME49 tachyzoites designed to ensure the formation of brain cysts. All pigs will be maintained until Day 90.
It is anticipated that the prevention of brain cyst formation (chronic infection) will be granted to the EP67-containing vaccines (or pooled vaccines) that most potently elicits lymphoproliferative and humoral responses.
Claims
1. An anti-parasitic compound comprising an N-terminal peptide antigen conjugated to a C- terminal peptide adjuvant via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism.
2. The anti-parasitic compound of claim 1, wherein said parasitic organism is a protozoan that is a causative agent of infection in humans or non-human animals.
3. The anti-parasitic compound of claim 2, wherein said protozoan is selected from the group consisting of Entamoeba histolytica, Eimeria spp. , Isospra spp. , Be noitia spp. , Babesia spp. , Balantidium coli , Giardia spp., Neospora caninum, Trichomonas vaginalis, Trypanosoma spp., Theileria spp., Leishmania spp., Toxoplasma gondii, Plasmodium spp., Sarcocystis spp., Spironucleus, Histomonas meleagridis, Cryptosporidium spp., Cytauxzoon felis, Cystoisospora belli, Tritrichomonas spp. , Pentatrichomonas hominis, and the like.
4. The anti -parasitic compound of claim 1, wherein said peptide analog is a hydrochloride salt form of EP67 YSFKDMP(MeL)aR (SEQ ID NO:2), or a conformationally-stable analog thereof, comprising the formula:
Tyr-Ser-Phe-Lys-Asp-Met-Xaa-(Xaa2)-(D-Ala)-Arg (SEQ ID NO: l), or HC1 salt form thereof, wherein Xaa is a modified proline residue or a residue substitution for proline, and Xaa2 is leucine or N-methyl leucine.
5. The anti -parasitic compound of claim 4, wherein Xaa2 is leucine or N-methyl leucine, and Xaa is selected from the group consisting of: a) alanine; b) N-methylalanine; b) 2- or 3- aminoisobutyric acid; c) cyclohexylalanine; d) N-methylisoleucine; e) singly-substituted proline analogs at the 2, 3, 4, and/or 5 positions of the pyrrolidine side chain; f) doubly-substituted proline analogs at the 2, 3, 4, and/or 5 positions of the pyrrolidine side chain; g) pseudoproline analog: cysteine-derived thiazolidine, serine-derived oxazolidine, or threonine-derived oxazolidine; h) trifluoromethylated pseudoprolines; i) proline analog or homolog having a constrained conformation; j) trifluoromethylated azetidine 2-carboxylic acid; k) trifluoromethylated homoserine; 1) oxetanyl-containing peptidomimetic; m) N-aminoimidazolidin-2-one analog; and
n) nonchiral pipecolic acid analog.
6. The anti-parasitic compound of claim 4, wherein the EP67 analog is YSFKDM(Aib)LaR (SEQ ID NO:3), Y SFKDM(dmP)(MeL)aR (SEQ ID NO:4) or Y SFKDM(Cha)LaR (SEQ ID NO: l, where Xaa is cyclohexylalanine and Xaa2 is leucine).
7. The anti -parasitic compound of claim 1, wherein said a peptide adjuvant is a peptide comprising the formula:
A 1 - Ser-Phe-Ly s- A2- A3 - A4- A5 - A6- A7 (SEQ ID NO: 5) or an HC1 salt form thereof and/or a conformationally-stable derivative thereof, wherein:
Al is Tyr, Trp, or N-acetyl derivatives of Tyr or Trp;
A2 is Asp, Gly, Pro or N-methyl derivatives of Asp or Gly;
A3 is Ala, Cys, Leu, Met or N-methyl derivatives of Ala, Cys, Leu or Met;
A4 is Gln, Leu, Pro or N-methyl derivatives of Gln or Leu;
A5 is Pro, Leu, a-methyl Leu or N-methyl Leu;
A6 is D-Ala, Gly, D-Pro, aminoisobutyric acid (Aib) or N-methyl derivatives of D- Ala or Gly; and
A7 is Arg or N-methyl Arg.
8. The anti-parasitic compound of claim 1, wherein said a peptide adjuvant is a peptide selected from the group consisting of: Tyr-Ser-Phe-Lys-Pro-Met-Pro-Leu-(D-Ala)-Arg (SEQ ID NO:6); Tyr-Ser-Phe-Lys-Asp-Ala-Pro-Leu-(D-Ala)-Arg (SEQ ID NO:7); Tyr-Ser-Phe-Lys-Asp- Met-Pro-Leu-(D-Ala)-Arg (SEQ ID NO:8); Tyr-Ser-Phe-Lys-Asp-Met-Pro-Leu-Gly-Arg (SEQ ID NO:9); Tyr-Ser-Phe-Lys-Asp-Ala-Pro-Leu-Gly-Arg (SEQ ID NO: 10); Tyr-Ser-Phe-Lys-Asp- Cys-Pro-Leu-Gly-Arg (SEQ ID NO: 11); Tyr-Ser-Phe-Lys-Asp-Met-Pro-Leu-(D-Pro)-Arg (SEQ ID NO: 12); Tyr-Ser-Phe-Lys-Asp-Met-Gln-Leu-(D-Ala)-Arg (SEQ ID NO: 13); Tyr-Ser-Phe- Lys-Asp-Met-Gln-Leu-Gly-Arg (SEQ ID NO: 14); Tyr-Ser-Phe-Lys-Asp-Met-Gln-Pro-Gly-Arg (SEQ ID NO: 15); Tyr-Ser-Phe-Lys-Asp-Met-Pro-Leu-Aib-Arg (SEQ ID NO: 16); Tyr-Ser-Phe- Lys-Gly-Met-Pro-Leu-Gly-Arg (SEQ ID NO: l7);Tyr-Ser-Phe-Lys-Gly-Leu-Leu-Leu-Gly-Arg (SEQ ID NO: 18); and HC1 salt forms thereof.
9. The anti-parasitic compound of claim 1, wherein said peptide antigen is an MHC class I- or class II-restricted antigenic peptide.
10. The anti -parasitic compound of claim 9, wherein said peptide antigen is restricted by human or non-human mammalian MHC class I or class II molecules.
11. The anti-parasitic compound of claim 1, wherein said anti-parasitic compound is a linear peptide of from about 12 to about 30 residues.
12. The anti-parasitic compound of claim 1, wherein said peptide antigen is selected from the group consisting of: SFKDILPKL SENP W Q (SEQ ID NO: 19), EEVIDTMKSMQRDEE (SEQ ID NO:20), CAELCDPSNKPGHLL(SEQ ID NO:2l), KRVTCGYPESGPVNL (SEQ ID NO:22), DRRPLHPGSVNEFDF (SEQ ID NO:23), and GLVAAALPQFATAAT(SEQ ID NO:24).
13. The anti-parasitic compound of claim 1, wherein said peptide antigen is conjugated to said peptide adjuvant by a protease cleavable linker.
14. The anti-parasitic compound of claim 13, wherein said cleavable linker comprises an arginine dipeptide.
15. A composition comprising the anti-parasitic compound according to any one of claims 1- 14 dispersed in a pharmaceutically acceptable carrier.
16. The composition of claim 15, further comprising preservatives, buffering agents, salts, and mixtures thereof.
17. The composition of claim 15, said composition comprising a plurality of said anti-parasitic compounds comprising at least two or more different anti-parasitic compounds each having different peptide antigens.
18. The composition of claim 17, said composition comprising at least 3 or more different anti- parasitic compounds each having different peptide antigens.
19. The composition of claim 17, said composition comprising at least 5 or more different anti- parasitic compounds each having different peptide antigens.
20. A method for therapeutic or prophylactic treatment of a parasitic infection, said method comprising administering an anti-parasitic compound according to any one of claims 1-14 to a subject in need thereof.
21. The method of claim 20, wherein said parasitic infection is caused by a pathogenic protozoan.
22. The method of claim 21, wherein said protozoan is selected from the group consisting of Entamoeba histolytica, Eimeria spp. , Isospra spp. , Besnoitia spp. , Babesia spp. , Balantidium coli , Giardia spp., Neospora caninum, Trichomonas vaginalis, Trypanosoma spp., Theileria spp., Leishmania spp., Toxoplasma gondii, Plasmodium spp., Sarcocystis spp., Spironucleus, Histomonas meleagridis, Cryptosporidium spp., Cytauxzoon felis, Cystoisospora belli, Tritrichomonas spp. , Pentatrichomonas hominis, and the like.
23. The method of claim 20, wherein said anti -parasitic compound is dispersed in a pharmaceutically-acceptable carrier.
24. The method of claim 23, further comprising providing a unit dosage form of said peptide analog dispersed in said pharmaceutically-acceptable carrier prior to said administering.
25. The method of claim 24, wherein said unit dosage form comprises a plurality of said anti- parasitic compounds comprising at least two or more different anti-parasitic compounds each having different peptide antigens.
26. The method of claim 25, said unit dosage form comprising at least 3 or more different anti- parasitic compounds each having different peptide antigens.
27. The method of claim 25, said unit dosage form comprising at least 5 or more different anti- parasitic compounds each having different peptide antigens.
28. The method of claim 20, wherein said anti-parasitic compound is administered intramuscularly, subcutaneously, intradermally, intranasally, intraperitoneally, intravenously, orally, or via a transdermal patch.
29. The method of claim 20, wherein said subject is a human or non-human mammal.
30. The method of claim 20, said compound selectively binding C5aR-bearing antigen presenting cells in said subject after said administering.
31. The method of claim 30, wherein said compound is taken up into said cells, said peptide antigen being cleaved from said peptide adjuvant, processed by said cells, and presented on a surface of said antigen presenting cells, wherein said presented peptide antigen induces an immune response against said parasitic infection in said subject.
32. The method of claim 30, wherein said compound does not bind to C5aR on pro- inflammatory cells.
33. Use of an anti-parasitic compound according to any one of claims 1-14 to prepare a therapeutic or prophylactic medicament for inducing an immune response against parasitic infection in a subject.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/275,892 US11911464B2 (en) | 2018-09-14 | 2019-09-13 | Anti-parasitic immunological compositions |
EP19859519.1A EP3849590A4 (en) | 2018-09-14 | 2019-09-13 | Anti-parasitic immunological compositions |
CA3154373A CA3154373A1 (en) | 2018-09-14 | 2019-09-13 | Anti-parasitic immunological compositions |
US18/428,425 US20240238414A1 (en) | 2018-09-14 | 2024-01-31 | Anti-parasitic immunological compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862731353P | 2018-09-14 | 2018-09-14 | |
US62/731,353 | 2018-09-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/275,892 A-371-Of-International US11911464B2 (en) | 2018-09-14 | 2019-09-13 | Anti-parasitic immunological compositions |
US18/428,425 Division US20240238414A1 (en) | 2018-09-14 | 2024-01-31 | Anti-parasitic immunological compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020056229A1 true WO2020056229A1 (en) | 2020-03-19 |
Family
ID=69777901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/050963 WO2020056229A1 (en) | 2018-09-14 | 2019-09-13 | Anti-parasitic immunological compositions |
Country Status (4)
Country | Link |
---|---|
US (2) | US11911464B2 (en) |
EP (1) | EP3849590A4 (en) |
CA (1) | CA3154373A1 (en) |
WO (1) | WO2020056229A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023056527A1 (en) * | 2021-10-07 | 2023-04-13 | The University Of Queensland | Proteinaceous molecules and uses therefor |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999066043A1 (en) * | 1998-06-12 | 1999-12-23 | Smithkline Beecham Biologicals S.A. | Recombinant production of toxoplasma sag1 antigen |
WO2002017960A1 (en) * | 2000-08-31 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Vaccines against toxoplasma gondii |
WO2004007525A2 (en) * | 2002-07-10 | 2004-01-22 | Akzo Nobel N. V. | Immunogenic composition comprising a fusion protein and a saponin adjuvant |
US7358087B2 (en) * | 1995-10-20 | 2008-04-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
US20080280307A1 (en) * | 2005-03-08 | 2008-11-13 | Nicola Gargano | Chimeric Recombinant Antigens of Toxoplasma Gondii |
US20150218516A1 (en) * | 2007-04-06 | 2015-08-06 | The Board Of Regents Of The University Of Nebraska | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895411B2 (en) | 2010-06-29 | 2018-02-20 | San Diego State University Research Foundation | Analogs of C5a and methods of using same |
US10220002B2 (en) * | 2011-12-02 | 2019-03-05 | Board Of Regents Of The University Of Nebraska | Controlled-release peptide compositions and uses thereof |
CN107847452A (en) * | 2015-03-11 | 2018-03-27 | 内布拉斯加大学董事会 | Response selectivity C5a activators EP67 conformational stability analog |
BR112019026336A2 (en) | 2017-06-12 | 2020-07-21 | Board Of Regents Of The University Of Nebraska | hydrochloride salt form of a c5a c-terminal analog peptide and the use thereof, composition, method to induce an immune response against an infection or cancer, kit and compound to increase an immune response to an immunogenic agent |
-
2019
- 2019-09-13 US US17/275,892 patent/US11911464B2/en active Active
- 2019-09-13 EP EP19859519.1A patent/EP3849590A4/en active Pending
- 2019-09-13 CA CA3154373A patent/CA3154373A1/en active Pending
- 2019-09-13 WO PCT/US2019/050963 patent/WO2020056229A1/en unknown
-
2024
- 2024-01-31 US US18/428,425 patent/US20240238414A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7358087B2 (en) * | 1995-10-20 | 2008-04-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
WO1999066043A1 (en) * | 1998-06-12 | 1999-12-23 | Smithkline Beecham Biologicals S.A. | Recombinant production of toxoplasma sag1 antigen |
WO2002017960A1 (en) * | 2000-08-31 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Vaccines against toxoplasma gondii |
WO2004007525A2 (en) * | 2002-07-10 | 2004-01-22 | Akzo Nobel N. V. | Immunogenic composition comprising a fusion protein and a saponin adjuvant |
US20080280307A1 (en) * | 2005-03-08 | 2008-11-13 | Nicola Gargano | Chimeric Recombinant Antigens of Toxoplasma Gondii |
US20150218516A1 (en) * | 2007-04-06 | 2015-08-06 | The Board Of Regents Of The University Of Nebraska | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
Non-Patent Citations (1)
Title |
---|
See also references of EP3849590A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023056527A1 (en) * | 2021-10-07 | 2023-04-13 | The University Of Queensland | Proteinaceous molecules and uses therefor |
Also Published As
Publication number | Publication date |
---|---|
US11911464B2 (en) | 2024-02-27 |
CA3154373A1 (en) | 2020-03-19 |
US20210290761A1 (en) | 2021-09-23 |
US20240238414A1 (en) | 2024-07-18 |
EP3849590A1 (en) | 2021-07-21 |
EP3849590A4 (en) | 2022-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4163291A1 (en) | Polypeptide vaccine coupled with tlr7 agonist for novel coronavirus and use thereof | |
US10350284B1 (en) | Antigen specific multi epitope-based anti-infective vaccines | |
El Bissati et al. | Adjuvanted multi-epitope vaccines protect HLA-A* 11: 01 transgenic mice against Toxoplasma gondii | |
US20240238414A1 (en) | Anti-parasitic immunological compositions | |
Dziadek et al. | Toxoplasma gondii: the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB/c mice | |
Cong et al. | Toxoplasma gondii HLA-B* 0702-restricted GRA720-28 peptide with adjuvants and a universal helper T cell epitope elicits CD8+ T cells producing interferon-γ and reduces parasite burden in HLA-B* 0702 mice | |
US9555086B2 (en) | Compositions and methods for inducing an immune response | |
KR20160131998A (en) | Oncology vaccine | |
EP2170372A1 (en) | Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis | |
KR19990022654A (en) | How to boost a protective immune response | |
Gong et al. | The protective effect of a DNA vaccine encoding the Toxoplasma gondii cyclophilin gene in BALB/c mice | |
SA110310855B1 (en) | The Use of an l3 and/or l5 Source as a Vaccine or as a Diagnostic for a Parasitic Disease | |
EP2501396B1 (en) | Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease | |
WO2006058243A2 (en) | Leishmania antigens and related compositions and uses | |
US11559575B2 (en) | Multi-epitopic peptide compounds and vaccines against leishmaniasis | |
US8299232B2 (en) | Constructing a DNA chimera for vaccine development against leishmaniasis and tuberculosis | |
US11969465B2 (en) | Toxoplasma gondii vaccines and their use | |
WO2023076539A2 (en) | A subunit cryptococcus vaccine | |
JP2023540779A (en) | Fusion protein containing coronavirus-derived receptor binding domain and nucleocapsid protein and its uses | |
WO2023148333A1 (en) | Co-vaccination with cd4 and cd8 antigens | |
BRPI0609847A2 (en) | immunogenic composition, polypeptide, variant polypeptide, nucleic acid molecule, vaccine, expression vector, and plasmids | |
Milan et al. | Recombinant protein and DNA vaccines derived from. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19859519 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019859519 Country of ref document: EP Effective date: 20210414 |
|
ENP | Entry into the national phase |
Ref document number: 3154373 Country of ref document: CA |